المؤلفون: O. V. Zhukova, E. I. Kasikhina, M. N. Ostretsova, S. S. Ismatullaeva, О. В. Жукова, Е. И. Касихина, М. Н. Острецова, С. С. Исматуллаева

المصدر: Meditsinskiy sovet = Medical Council; № 2 (2023); 62-67 ; Медицинский Совет; № 2 (2023); 62-67 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: монотерапия, topical retinoids, adapalene, retinoic acid, monotherapy, наружные ретиноиды, адапален, ретиноевая кислота

وصف الملف: application/pdf

العلاقة: https://www.med-sovet.pro/jour/article/view/7389/6590Test; Tan J.K., Bhate K. A global perspective on the epidemiology of acne. Br J Dermatol. 2015;172(Suppl. 1):3–12. https://doi.org/10.1111/bjd.13462Test.; Burton J.L., Cunliffe W.J., Stafford I., Shuster S. The prevalence of acne vulgaris in adolescence. Br J Dermatol. 1971;85(2):119–126. https://doi.org/10.1111/j.1365-2133.1971.tb07195.xTest.; Wang Y., Xiao S., Ren J., Zhang Y. Analysis of the epidemiological burden of acne vulgaris in China based on the data of global burden of disease 2019. Front Med (Lausanne). 2022;9:939584. https://doi.org/10.3389/fmed.2022.939584Test.; Dréno B. Treatment of adult female acne: a new challenge. J Eur Acad Dermatol Venereol. 2015;29(Suppl. 5):14–19. https://doi.org/10.1111/jdv.13188Test.; Rueda L.J., Porras A., Rico A. Prevalence of adult female acne in Colombia: A population-based study. Int J Womens Dermatol. 2021;7(5 Part B):727–730. https://doi.org/10.1016/j.ijwd.2021.06.003Test.; Svensson A., Ofenloch R.F., Bruze M., Naldi L., Cazzaniga S., Elsner P. et al. Prevalence of skin disease in a population-based sample of adults from five European countries. Br J Dermatol. 2018;178(5):1111–1118. https://doi.org/10.1111/bjd.16248Test.; Semedo D., Ladeiro F., Ruivo M., D’Oliveira C., De Sousa F., Gayo M. et al. Adult Acne: Prevalence and Portrayal in Primary Healthcare Patients, in the Greater Porto Area, Portugal. Acta Med Port. 2016;29(9):507–513. https://doi.org/10.20344/amp.6626Test.; Perkins A.C., Maglione J., Hillebrand G.G., Miyamoto K., Kimball A.B. Acne vulgaris in women: prevalence across the life span. J Womens Health (Larchmt). 2012;21(2):223–230. https://doi.org/10.1089/jwh.2010.2722Test.; Collier C.N., Harper J.C., Cafardi J.A., Cantrell W.C., Wang W., Foster K.W., Elewski B.E. The prevalence of acne in adults 20 years and older. J Am Acad Dermatol. 2008;58(1):56–59. https://doi.org/10.1016/j.jaad.2007.06.045Test.; Poli F., Dreno B., Verschoore M. An epidemiological study of acne in female adults: results of a survey conducted in France. J Eur Acad Dermatol Venereol. 2001;15(6):541–545. https://doi.org/10.1046/j.1468-3083.2001.00357.xTest.; Goulden V., Clark S.M., Cunliffe W.J. Post-adolescent acne: a review of clinical features. Br J Dermatol. 1997;136(1):66–70. Available at: https://pubmed.ncbi.nlm.nih.gov/9039297Test/.; Kutlu Ö., Karadağ A.S., Wollina U. Adult acne versus adolescent acne: a narrative review with a focus on epidemiology to treatment. An Bras Dermatol. 2023;98(1):75–83. https://doi.org/10.1016/j.abd.2022.01.006Test.; Bagatin E., Freitas T.H.P., Rivitti-Machado M.C., Machado M.C.R., Ribeiro B.M., Nunes S., Rocha M.A.D.D. Adult female acne: a guide to clinical practice. An Bras Dermatol. 2019;94(1):62–75. https://doi.org/10.1590/abd1806-4841.20198203Test.; Khunger N., Kumar C. A clinico-epidemiological study of adult acne: is it different from adolescent acne? Indian J Dermatol Venereol Leprol. 2012;78(3):335–341. https://doi.org/10.4103/0378-6323.95450Test.; Skroza N., Tolino E., Mambrin A., Zuber S., Balduzzi V., Marchesiello A. et al. Adult Acne Versus Adolescent Acne: A Retrospective Study of 1,167 Patients. J Clin Aesthet Dermatol. 2018;11(1):21–25. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5788264Test/.; Rajegowda H.M., Suman B.S., Basavapura Madegowda S.K., Kalegowda D., Shettar Rajendra B.S. A clinicoepidemiological study of adult acne among females: Is it surpassing the adolescent acne? Clin Dermatol Rev. 2021;5(1):71–77. https://doi.org/10.4103/CDR.CDR_55_20Test.; Zeichner J.A., Baldwin H.E., Cook-Bolden F.E., Eichenfield L.F., Fallon- Friedlander S., Rodriguez D.A. Emerging Issues in Adult Female Acne. J Clin Aesthet Dermatol. 2017;10(1):37–46. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5300732Test/.; Williams C., Layton A.M. Persistent acne in women: implications for the patient and for therapy. Am J Clin Dermatol. 2006;7(5):281–290. https://doi.org/10.2165/00128071-200607050-00002Test.; Dumont-Wallon G., Dréno B. Acné de la femme de plus de 25 ans: spécifique par sa clinique et les facteurs favorisants Etude rétrospective de 79 femmes. Presse Med. 2008;37(4 Pt 1):585–591. https://doi.org/10.1016/j.lpm.2007.07.014Test.; Branisteanu D.E., Toader M.P., Porumb E.A., Serban I.L., Pinzariu A.C., Branisteanu C.I. et al. Adult female acne: Clinical and therapeutic particularities (Review). Exp Ther Med. 2022;23(2):151. https://doi.org/10.3892/etm.2021.11074Test.; Rocha M.A., Bagatin E. Adult-onset acne: prevalence, impact, and management challenges. Clin Cosmet Investig Dermatol. 2018;11:59–69. https://doi.org/10.2147/CCID.S137794Test.; Cappel M., Mauger D., Thiboutot D. Correlation between serum levels of insulin-like growth factor 1, dehydroepiandrosterone sulfate, and dihydrotestosterone and acne lesion counts in adult women. Arch Dermatol. 2005;141(3):333–338. https://doi.org/10.1001/archderm.141.3.333Test.; Albalat W., Darwish H., Abd-Elaal W.H., AbouHadeed M.H., Essam R. The potential role of insulin-like growth factor 1 in acne vulgaris and its correlation with the clinical response before and after treatment with metformin. J Cosmet Dermatol. 2022;21(11):6209–6214. https://doi.org/10.1111/jocd.15210Test.; Heng A.H.S., Chew F.T. Systematic review of the epidemiology of acne vulgaris. Sci Rep. 2020;10(1):5754. https://doi.org/10.1038/s41598-020-62715-3Test.; Passeron T., Zouboulis C.C., Tan J., Andersen M.L., Katta R., Lyu X. et al. Adult skin acute stress responses to short-term environmental and internal aggression from exposome factors. J Eur Acad Dermatol Venereol. 2021;35(10):1963–1975. https://doi.org/10.1111/jdv.17432Test.; Bernard J.J., Gallo R.L., Krutmann J. Photoimmunology: how ultraviolet radiation affects the immune system. Nat Rev Immunol. 2019;19(11):688–701. https://doi.org/10.1038/s41577-019-0185-9Test.; Levin J. The Relationship of Proper Skin Cleansing to Pathophysiology, Clinical Benefits, and the Concomitant Use of Prescription Topical Therapies in Patients with Acne Vulgaris. Dermatol Clin. 2016;34(2):133–145. https://doi.org/10.1016/j.det.2015.11.001Test.; Preneau S., Dreno B. Female acne – a different subtype of teenager acne? J Eur Acad Dermatol Venereol. 2012;26(3):277–282. https://doi.org/10.1111/j.1468-3083.2011.04214.xTest.; Choi C.W., Lee D.H., Kim H.S., Kim B.Y., Park K.C., Youn S.W. The clinical features of late onset acne compared with early onset acne in women. J Eur Acad Dermatol Venereol. 2011;25(4):454–461. https://doi.org/10.1111/j.1468-3083.2010.03813.xTest.; Silpa-Archa N., Kohli I., Chaowattanapanit S., Lim H.W., Hamzavi I. Postinflammatory hyperpigmentation: A comprehensive overview: Epidemiology, pathogenesis, clinical presentation, and noninvasive assessment technique. J Am Acad Dermatol. 2017;77(4):591–605. https://doi.org/10.1016/j.jaad.2017.01.035Test.; Dréno B., Thiboutot D., Layton A.M., Berson D., Perez M., Kang S. Large-scale international study enhances understanding of an emerging acne population: adult females. J Eur Acad Dermatol Venereol. 2015;29(6):1096–1106. https://doi.org/10.1111/jdv.12757Test.; Dréno B., Poli F., Pawin H., Beylot C., Faure M., Chivot M. et al. Development and evaluation of a Global Acne Severity Scale (GEA Scale) suitable for France and Europe. J Eur Acad Dermatol Venereol. 2011;25(1):43–48. https://doi.org/10.1111/j.1468-3083.2010.03685.xTest.; Auffret N., Claudel J.P., Leccia M.T., Poli F., Farhi D., Dréno B. AFAST – Adult Female Acne Scoring Tool: an easy-to-use tool for scoring acne in adult females. J Eur Acad Dermatol Venereol. 2016;30(5):824–828. https://doi.org/10.1111/jdv.13518Test.; Kolli S.S., Pecone D., Pona A., Cline A., Feldman S.R. Topical Retinoids in Acne Vulgaris: A Systematic Review. Am J Clin Dermatol. 2019;20(3):345–365. https://doi.org/10.1007/s40257-019-00423-zTest.; Mavranezouli I., Daly C.H., Welton N.J., Deshpande S., Berg L., Bromham N. et al. A systematic review and network meta-analysis of topical pharmacological, oral pharmacological, physical and combined treatments for acne vulgaris. Br J Dermatol. 2022;187(5):639–649. https://doi.org/10.1111/bjd.21739Test.; Stuart B., Maund E., Wilcox C., Sridharan K., Sivaramakrishnan G., Regas C. et al. Topical preparations for the treatment of mild-to-moderate acne vulgaris: systematic review and network meta-analysis. Br J Dermatol. 2021;185(3):512–525. https://doi.org/10.1111/bjd.20080Test.; Eichenfield D.Z., Sprague J., Eichenfield L.F. Management of Acne Vulgaris: A Review. JAMA. 2021;326(20):2055–2067. https://doi.org/10.1001/jama.2021.17633Test.; Thiboutot D.M., Dréno B., Abanmi A., Alexis A.F., Araviiskaia E., Barona Cabal M.I. et al. Practical management of acne for clinicians: An international consensus from the Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2018;78(2 Suppl. 1):S1–S23.e1. https://doi.org/10.1016/j.jaad.2017.09.078Test.; Катханова О.А., Катханов А.М. Опыт использования топических ретиноидов и азелаиновой кислоты в терапии акне. Клиническая дерматология и венерология. 2015;14(6):120–125. https://doi.org/10.17116/klinderma2015146120-125Test.; Berson D., Alexis A. Adapalene 0.3% for the treatment of acne in women. J Clin Aesthet Dermatol. 2013;6(10):32–35. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3805304Test/.; Hess J., Angel P., Schorpp-Kistner M. AP-1 subunits: quarrel and harmony among siblings. J Cell Sci. 2004;117(Pt 25):5965–5973. https://doi.org/10.1242/jcs.01589Test.; Leyden J., Stein-Gold L., Weiss J. Why Topical Retinoids Are Mainstay of Therapy for Acne. Dermatol Ther (Heidelb). 2017;7(3):293–304. https://doi.org/10.1007/s13555-017-0185-2Test.; Jain S. Topical tretinoin or adapalene in acne vulgaris: an overview. J Dermatolog Treat. 2004;15(4):200–207. https://doi.org/10.1080/09546630410033006Test.; Crooks S.W., Stockley R.A. Leukotriene B4. Int J Biochem Cell Biol. 1998;30(2):173–178. https://doi.org/10.1016/s1357-2725Test(97)00123-4.; https://www.med-sovet.pro/jour/article/view/7389Test

الإتاحة: https://doi.org/10.21518/ms2023-030Test
https://doi.org/10.1111/bjd.13462Test
https://doi.org/10.1111/j.1365-2133.1971.tb07195.xTest
https://doi.org/10.3389/fmed.2022.939584Test
https://doi.org/10.1111/jdv.13188Test
https://doi.org/10.1016/j.ijwd.2021.06.003Test
https://doi.org/10.1111/bjd.16248Test
https://doi.org/10.20344/amp.6626Test
https://doi.org/10.1089/jwh.2010.2722Test
https://doi.org/10.1016/j.jaad.2007.06.045Test

المؤلفون: V. A. Otdelenov, Yu. Yu. Kiselev, K. B. Mirzaev, A. V. Matveev, D. A. Sychev

المصدر: Качественная клиническая практика, Vol 0, Iss 4S, Pp 53-59 (2020)

مصطلحات موضوعية: коронавирус, монотерапия гидроксихлорохином, гидроксихлорохин с азитромицином, covid-19, Medical technology, R855-855.5, Pharmacy and materia medica, RS1-441

وصف الملف: electronic resource

العلاقة: https://www.clinvest.ru/jour/article/view/527Test; https://doaj.org/toc/2588-0519Test; https://doaj.org/toc/2618-8473Test

الوصول الحر: https://doaj.org/article/277ef40b470e486eb66c951af4df2b9bTest

المؤلفون: Kovalyova J.S., Kokina O.A., Vedler A.A., Karkhova V.V., Makarenko E.S., Pisarev V.V., Merkulov M.E.

المساهمون: Исследование проводилось при финансовой поддержке АО «ВЕРТЕКС»., The study was financially supported by Vertex JSC.

المصدر: Vestnik dermatologii i venerologii; Vol 98, No 3 (2022); 70-79 ; Вестник дерматологии и венерологии; Vol 98, No 3 (2022); 70-79 ; 2313-6294 ; 0042-4609 ; 10.25208/vdv.983

مصطلحات موضوعية: onychomycosis, terbinafine, econazole, ciclopirox, local monotherapy, a randomized clinical trial, онихомикоз, тербинафин, эконазол, циклопирокс, локальная монотерапия, рандомизированное клиническое исследование

وصف الملف: application/pdf

العلاقة: https://vestnikdv.ru/jour/article/view/1303/pdfTest; https://vestnikdv.ru/jour/article/view/1303/pdf_1Test; https://vestnikdv.ru/jour/article/view/1303/pdf_2Test; https://vestnikdv.ru/jour/article/downloadSuppFile/1303/886Test; https://vestnikdv.ru/jour/article/downloadSuppFile/1303/910Test; https://vestnikdv.ru/jour/article/downloadSuppFile/1303/911Test; https://vestnikdv.ru/jour/article/downloadSuppFile/1303/1198Test; https://vestnikdv.ru/jour/article/downloadSuppFile/1303/1199Test; https://vestnikdv.ru/jour/article/view/1303Test

الإتاحة: https://doi.org/10.25208/vdv1303Test
https://doi.org/10.25208/vdv.983Test
https://vestnikdv.ru/jour/article/view/1303Test

المؤلفون: S. К. Zyryanov, I. N. Dyakov, С. К. Зырянов, И. Н. Дьяков

المصدر: FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology; Vol 15, No 2 (2022); 188-198 ; ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология; Vol 15, No 2 (2022); 188-198 ; 2070-4933 ; 2070-4909

مصطلحات موضوعية: реальная клиническая практика, COPD, GOLD D, tiotropium bromide + olodaterol, monotherapy, combination therapy, budget impact, exacerbations, long-acting bronchodilator, long-acting M-cholinolytic, real clinical practice, ХОБЛ, тиотропия бромид + олодатерол, монотерапия, комбинированная терапия, влияние на бюджет, обострения, бронходилататор длительного действия, М-холинолитик длительного действия

وصف الملف: application/pdf

العلاقة: https://www.pharmacoeconomics.ru/jour/article/view/688/423Test; Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2020 Report. URL: https://goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdfTest (дата обращения 03.06.2022).; Хроническая обструктивная болезнь легких. Клинические рекомендации. Минздрав РФ. 2021. URL: https://cr.minzdrav.gov.ru/recomend/603_2Test (дата обращения 03.06.2022).; Lamprecht B., McBurnie M.A., Vollmer W.M., et al. COPD in never smokers: results form the population-based burden of obstructive lung disease study. Chest. 2011; 139 (4): 752–63. https://doi.org/10.1378/chest.10-1253Test.; Chuchalin A.G., Khaltaev N., Antonov N.S., et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int J Chron Obstruct Pulmon Dis. 2014; 9: 963–74. https://doi.org/10.2147/COPD.S67283Test.; Nguyen T. Evidence-informed policy making: bridging the gap. Public Health Panorama. 2016; 2: 257.; van der Molen T., Cazzola M. Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. Prim Care Respir J. 2012; 21 (1): 101–8. https://doi.org/10.4104/pcrj.2011.00102Test.; Mahler D.A., Decramer M., D’Urzo A., et al. Dual bronchodilatation with QVA149 reduces patient reported dyspnea in COPD: the BLAZE study. Eur Respir J. 2014; 43 (6): 1599–609. https://doi.org/10.1183/09031936.00124013Test.; Arkhipov V., Arkhipova D., Miravitlles M., et al. Characteristics of COPD patients according to GOLD classification and clinical phenotypes in the Russian Federation: the SUPPORT trial. Int J Chron Obstruct Pulmon Dis. 2017; 12: 3255–62. https://doi.org/10.2147/COPD.S142997Test.; Calverley P.M., Anzueto A.R., Carter K., et al. Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial. Lancet Respir Med. 2018; 6 (5): 337–44. https://doi.org/10.1016/S2213-2600Test(18)30102-4.; Decramer M.L., Chapman K.R., Dahl R., et al. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir Med. 2013; 1 (7): 524–33. https://doi.org/10.1016/S2213-2600Test(13)70158-9.; Sethi S., Kerwin E., Watz H., et al. AMPLIFY: a randomized, phase III study evaluating the efficacy and safety of aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPD. Int J Chron Obstruct Pulmon Dis. 2019; 14: 667–82. https://doi.org/10.2147/COPD.S189138Test.; Государственный реестр предельных отпускных цен. URL: https://grls.rosminzdrav.ru/pricelims.aspxTest (дата обращения 03.06.2022).; Постановление Правительства РФ от 28.12.2021 № 2505. «О Программе государственных гарантий бесплатного оказания гражданам медицинской помощи на 2022 год и на плановый период 2023 и 2024 годов». URL: https://base.garant.ru/403335795Test/ (дата обращения 03.06.2022).; Приказ Минздрава России от 20.12.2012 № 1214н «Об утверждении стандарта первичной медико-санитарной помощи при обострении хронической обструктивной болезни легких». URL: https://minzdrav.gov-murman.ru/documents/poryadki-okazaniya-meditsinskoy-pomoshchi/pr_MZ_RF_1214.pdfTest (дата обращения 03.06.2022).; Федеральная служба государственной статистики. URL: https://rosstat.gov.ruTest (дата обращения 03.06.2022).; Karner C., Cates C.J. Combination inhaled steroid and long-acting beta2-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2011; 3: CD008532. https://doi.org/10.1002/14651858.CD008532.pub2Test.; https://www.pharmacoeconomics.ru/jour/article/view/688Test

الإتاحة: https://doi.org/10.17749/2070-4909/farmakoekonomika.2022.144Test
https://doi.org/10.1378/chest.10-1253Test
https://doi.org/10.2147/COPD.S67283Test
https://doi.org/10.4104/pcrj.2011.00102Test
https://doi.org/10.1183/09031936.00124013Test
https://doi.org/10.2147/COPD.S142997Test
https://doi.org/10.1016/S2213-2600Test(18)30102-4
https://doi.org/10.1016/S2213-2600Test(13)70158-9
https://doi.org/10.2147/COPD.S189138Test
https://doi.org/10.1002/14651858.CD008532.pub2Test

المؤلفون: I. O. Borovikov, I. I. Kutsenko, V. P. Bulgakova, A. A. Gorbulina, И. О. Боровиков, И. И. Куценко, В. П. Булгакова, А. А. Горбулина

المصدر: Meditsinskiy sovet = Medical Council; № 16 (2022); 75-83 ; Медицинский Совет; № 16 (2022); 75-83 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: иммуностимулятор, mild cervical intraepithelial neoplasia, inosine pranobex, monotherapy, immunostimulant, цервикальная интраэпителиальная неоплазия легкой степени, инозин пранобекс, монотерапия

وصف الملف: application/pdf

العلاقة: https://www.med-sovet.pro/jour/article/view/7093/6367Test; Зароченцева Н. В. Цервикальные интраэпителиальные неоплазии: современный взгляд на проблему и пути решения / Н. В. Зароченцева, Л. К. Джиджихия // Акушерство и гинекология: новости мнения, обучение. – 2016. – (4): 92–101. Режим доступа: https://acu-gin-journal.ru/ru/jarticles_acu/263.html?SSr=4601348bf011ffffffff27c__07e6090c0b2e13-3ed1Test. – Zarochentseva N. V., Dzhidzhikhiya L. K. Cervical intraepithelial neoplasia: a modern view on the problem and solutions. Akusherstvo i Ginekologiya: Novosti, Mneniya, Obuchenie. 2016; (4): 92–101. (In Russ.) Available at: https://acu-gin-journal.ru/ru/jarticles_acu/263.html?SSr=4601348b-f011ffffffff27c__07e6090c0b2e13-3ed1Test.; Jain M. A., Limaiem F. Cervical Intraepithelial Squamous Cell Lesion. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2022. Available at: https://pubmed.ncbi.nlm.nih.gov/32644501Test.; Nourrisson A., Lepetit H., Marty M., Garrigue I., Brun J. L. Regression of cervical high-grade squamous intraepithelial lesions (HSIL / CIN2) managed expectantly. J Gynecol Obstet Hum Reprod. 2022; 51 (8): 102442. https://doi.org/10.1016/j.jogoh.2022.102442Test.; Винокурова С. В. Генетические и эпигенетические механизмы регуляции вирусов папиллом человека / С. В. Винокурова // Успехи молекулярной онкологии. – 2016. – (3): 18–25. URL: https://umo.abvpress.ru/jour/article/view/58?locale=ru_RUTest. – Vinokurova S. V. Genetic and epigenetic mechanisms of regulation of human papillomaviruses. Uspehi Molekularnoj Onkologii. 2016; (3): 18–25. (In Russ.) URL: https://umo.abvpress.ru/jour/article/view/58?locale=ru_RUTest.; Cokan A., Pakiž M., Serdinšek T., Dovnik A., Kodrič T., Repše Fokter A. et al. Comparison of Conservative Treatment of Cervical Intraepithelial Lesions with Imiquimod with Standard Excisional Technique Using LLETZ: A Randomized Controlled Trial. J Clin Med. 2021; 10 (24): 5777. https://doi.org/10.3390/jcm10245777Test.; Ордиянц И. М. Рецидивирование ВПЧ-инфекции после комбинированного лечения заболеваний шейки матки / И. М. Ордиянц, Н. В. Буянова, М. Б. Абдурахманова // Акушерство и гинекология: новости, мнения, обучение. – 2018. – (3): 47–52. Режим доступа: https://acu-gin-journal.ru/ru/jarticles_acu/366.html?SSr=4601348bf011ffffffff27c__07e6090c0b2e13-3ed1Test. – Ordiyants I. M., Buyanova N. V., Abdurakhmanova M. B. Recurrence of HPV infection after combination therapy of uterine cervical diseases. Akusherstvo i Ginekologiya: Novosti, Mneniya, Obuchenie. 2018; (3): 47–52. (In Russ.) Available at: https://acu-gin-journal.ru/ru/jarticles_acu/366.html?SSr=4601348bf011ffffffff27c__07e6090c0b2e13-3ed1Test.; Yang Y., Zhang L., Qi R., Huo W., Li X., Wu X. et al. Treatment of high-risk human papillomavirus infection in low grade cervical squamous intraepithelial lesion with mild local thermotherapy: Three case reports. Medicine (Baltimore). 2020; 99 (27): e21005. https://doi.org/10.1097/MD.0000000000021005Test.; Kovachev S. M. Immunotherapy in patients with local HPV infection and high-grade squamous intraepithelial lesion following uterine cervical conization. Immunopharmacol Immunotoxicol. 2020; 42 (4): 314–318. https://doi.org/10.1080/08923973.2020.1765374Test.; Wang H., He Z., Han X., Zhang D., Zhang S. Prediction value with a novel and accurate tissue-based human papillomavirus detection method in low-grade squamous intraepithelial lesions. Cancer Med. 2022; 11 (13): 2576–2587. https://doi.org/10.1002/cam4.4634Test.; Zang L., Hu Y. Risk factors associated with HPV persistence after conization in high-grade squamous intraepithelial lesion. Arch Gynecol Obstet. 2021; 304 (6): 1409–1416. https://doi.org/10.1007/s00404-021-06217-1Test.; López-Filloy M., Cortez F. J., Gheit T., Cruz Y Cruz O., Cruz- Talonia F., Chávez-Torres M. et al. Altered Vaginal Microbiota Composition Correlates with Human Papillomavirus and Mucosal Immune Responses in Women with Symptomatic Cervical Ectopy. Front Cell Infect Microbiol. 2022; 12: 884272. https://doi.org/10.3389/fcimb.2022.884272Test.; Kawano K., Tsuda N., Nasu H., Tasaki S., Park J., Tasaki K. et al. Hum an papillomavirus genotyping predicts residual / recurrent disease after local treatment for cervical intraepithelial neoplasia better than viral DNA testing. J Obstet Gynaecol Res. 2021; 47 (10): 3628–3633. https://doi.org/10.1111/jog.14931Test.; Боровиков И. О. Опыт применения иммуномодулирующего препарата в терапии папилломавирусной инфекции гениталий у женщин / И. О. Боровиков, И. И. Куценко, Х. И. Горринг // Акушерство и гинекология. – 2018. – (3): 122–128. https://doi.org/10.18565/aig.2018.3.122-128Test. – Borovikov I. O., Kutsenko I. I., Gorring H. I. Experience the use of immunomodulatory drug in the therapy of papillomavirus infection genitalia in women. Akusherstvo i Ginekologiya (Russian Federation). 2018; (3): 122–128. (In Russ.) https://doi.org/10.18565/aig.2018.3.122-128Test.; Адамян Л. В. Цервикальная интраэпителиальная неоплазия, эрозия и эктропион шейки матки: клинические рекомендации / Л. В. Адамян [и др.] – М., 2020. – 56 с. Режим доступа: https://roag-portal.ru/recommendations_gynecologyTest. – Adamyan L. V., Apolikhina I. A., Artymuk N. V., Ashrafyan L. A., Bayramov G. R., Belokrinitskaya T. E. Cervical intraepithelial neoplasia, cervical erosion and ectropion: clinical guidelines. Moscow; 2020. 56 р. (In Russ.) Available at: https://roag-portal.ru/recommendations_gynecologyTest.; Байрамова Г. Р. Заболевания нижних отделов гениталий, ассоциированные с папилломавирусной инфекцией: радикальное лечение или иммунотерапия? / Г. Р. Байрамова [и др.] // Акушерство и гинекология: новости, мнения, обучение. – 2017. – (4): 13–19. Режим доступа: https://acu-gin-journal.ru/ru/jarticles_acu/318.html?SSr=4601348bf011ffffffff27c__07e6090c0b2e13-3ed1Test. – Bayramova G. R., Baranov I. I., Arslanyan K. N., Amirkhanyan A. S., Chernova V. F. Human papillomavirus-related diseases of lower genital tract: curative treatment or immunotherapy? Akusherstvo i Ginekologiya: Novosti, Mneniya, Obuchenie. 2017; (4): 13–19. (In Russ.) Available at: https://acu-gin-journal.ru/ru/jarticles_acu/318.html?SSr=4601348bf011ffffffff27c__07e6090c0b2e13-3ed1Test.; Межевитинова Е. А. Дисплазия шейки матки. Роль цитокинотерапии в повышении эффективности лечения / Е. А. Межевитинова, А. Е. Донников, В. Н. Прилепская // Акушерство и гинекология: новости мнения, обучение. – 2019. – (4): 66–71. Режим доступа: https://acu-gin-journal.ru/ru/jarticles_acu/458.html?Sr=-4601348bf011ffffffff27c__07e6090c0b2e13-3ed1Test. – Mezhevitinova E. A., Donnikov A. E., Prilepskaya V. N. Cervical intraepithelial neoplasia. Role of cytokine therapy in treatment efficiency improvement. Akusherstvo i Ginekologiya: Novosti, Mneniya, Obuchenie. 2019; (4): 66–71. (In Russ.) Available at: https://acu-gin-journal.ru/ru/jarticles_acu/458.html?SSr=4601348bf011ffffffff27c__07e6090c0b2e13-3ed1Test.; Абакарова П. Р. Локальная цитокинотерапия в комплексном лечении ВПЧ-ассоциированных заболеваний шейки матки / П. Р. Абакарова [и др.] // Гинекология. – 2019. –(1): 28–32. https://doi.org/10.26442/20795696.2019.1.190284Test. – Abakarova P. R., Prilepskaya V. N., Mezhevitinova E. A., Donnikov A. E. Local cytokine therapy in a comprehensive treatment of HPV-associated cervical diseases. Gynecology. 2019; (1): 28–32. (In Russ.) https://doi.org/10.26442/20795696.2019.1.190284Test.; Дубровина С. О. К вопросу о диагностике, профилактике и терапии патологии шейки матки / С. О. Дубровина, О. А. Ардинцева, Л. В. Красильникова // Гинекология. – 2018. –(5): 33–36. https://doi.org/10.26442/2079-5696_2018.5.33-36Test. – Dubrovina S. O., Ardintseva O. A., Krasilnikova L. V. To the question about diagnostics, prevention and therapy of pathology of the cervix. Gynecology. 2018; (5): 33–36. (In Russ.) https://doi.org/10.26442/2079-5696_2018.5.33-36Test.; Ткаченко Л. В. Иммунологическое обоснование комплексной терапии пациенток с ВПЧ-ассоциированной цервикальной интраэпителиальной неоплазией легкой степени / Л. В. Ткаченко [и др.] // Медицинский совет. – 2022. – (5): 118–127. https://doi.org/10.21518/2079-701X-2022-16-5-118-127Test. – Tkachenko L. V., Sviridova N. I., Skladanovskaya T. V., Gritsenko I. A., Shishimorova S. V. Immunological substantiation of complex therapy in patients with mild HPV-associated cervical intraepithelial neoplasia. Meditsinskiy Sovet. 2022; (5): 118–127. (In Russ.) https://doi.org/10.21518/2079-701X-2022-16-5-118-127Test.; Клинышкова Т. В. Влияние инозин пранобекса на экспрессию р16, Ki-67 у больных с ВПЧ-ассоциированными цервикальными интраэпителиальными неоплазиями / Т. В. Клинышкова, О. Н. Миронова // Гинекология. – 2018. – (4): 29–34. https://doi.org/10.26442/2079-5696_2018.4.29-34Test. – Klinyshkova T. V., Mironova O. N. Effect of inosine pranobex on p16, Ki-67 expression in patients with HPV-associated cervical intraepithelial neoplasia. Gynecology. 2018; (4): 29–34. (In Russ.) https://doi.org/10.26442/2079-5696_2018.4.29-34Test.; Kovachev S. M. A Review on Inosine Pranobex Immunotherapy for Cervical HPV-Positive Patients. Infect Drug Resist. 2021; 14: 2039–2049. https://doi.org/10.2147/IDR.S296709Test.; Salvadó A., Miralpeix E., Solé- Sedeno J. M., Kanjou N., Lloveras B., Duran X., Mancebo G. Predictor factors for conservative management of cervical intraepithelial neoplasia grade 2: Cytology and HPV genotyping. Gynecol Oncol. 2021; 162 (3): 569–574. https://doi.org/10.1016/j.ygyno.2021.06.019Test.; Абакарова П. Р. ВПЧ-ассоциированные заболевания шейки матки. Возможности комплексной терапии / П. Р. Абакарова, В. Н. Прилепская // Гинекология. – 2017. – (5): 4–9. Режим доступа: https://gynecology.orscience.ru/2079-5831/article/view/30007Test. – Abakarova P. R., Prilepskaya V. N. HPV-associated diseases of the cervix. Complex therapy options. Gynecology. 2017; (5): 4–9. (In Russ.) Available at: https://gynecology.orscience.ru/2079-5831/article/view/30007Test.; Роговская С. И. Регрессия генитальных кондилом и цервикальной интраэпителиальной неоплазии легкой степени на фоне иммунотерапии (клиническое наблюдение) / С. И. Роговская, Т. Н. Бебнева // РМЖ. Мать и дитя. – 2020. –(2): 100–104. https://doi.org/10.32364/2618-8430-2020-3-2-100-104Test. – Rogovskaya S. I., Bebneva T. N. Regression of genital papules and mild cervical intraepithelial neoplasia during immunotherapy (clinical case). Russian Journal of Woman and Child Health. 2020; (2): 100–104. (In Russ.) https://doi.org/10.32364/2618-8430-2020-3-2-100-104Test.; Morisky D., Green L., Levine D. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 2006; 24 (1): 67–74. https://doi.org/10.1097/00005650-198601000-00007Test.; Бицадзе В. О. Место иммуномодуляторов в контроле ВПЧ-ассоциированных заболеваний: проблемы и перспективы / В. О. Бицадзе, Н. М. Хамани, Н. А. Макацария // Акушерство, гинекология и репродукция. – 2016. – (3): 76–84. https://doi.org/10.17749/2313-7347.2016.10.2.076-084Test. – Bitsadze V. O., Khamani N. M., Makatsariya N. A. Role of inosine pranobex in management of HPV-associated diseases: problems and prospective. Obstetrics, Gynecology and Reproduction. 2016; (3): 76–84. (In Russ.) https://doi.org/10.17749/2313-7347.2016.10.2.076-084Test.; Рахматулина М. Р. Комплексная терапия папилломавирусной инфекции / М. Р. Рахматулина // Акушерство и гинекология. – 2017. – (12): 122–125. https://doi.org/10.18565/aig.2017.12.122-125Test. – Rakhmatulina M. R. Complex therapy of papillomavirus infection. Akusherstvo i Ginekologiya (Russian Federation). 2017; (12): 122–125. (In Russ.) https://doi.org/10.18565/aig.2017.12.122-125Test.; Елисеева М. И. Противовирусное действие изопринозина при ВПЧ-ассоциированных заболеваниях / М. И. Елисеева [и др.] // Акушерство и гинекология. – 2012. – (2): 107–114. Режим доступа: https://aig-journal.ru/articles/Protivovirusnyi-effekt-inozina-pranobeksa-pri-VPCh-associirovannyh-zabolevaniyah.htmlTest. – Eliseeva M. I., Manukhin I. B., Mynbaev O. A., Zvereva N. S., Mishutina A. A., Tkarev V. N. Antiviral effect of isoprinosine in HPV-associated diseases. Akusherstvo i Ginekologiya (Russian Federation). 2012; (2): 107–114. (In Russ.) Available at: https://aig-journal.ru/articles/Protivovirusnyi-effekt-inozina-pranobeksa-pri-VPCh-associirovannyh-zabolevaniyah.htmlTest.; Пестрикова Т. Ю. Оценка эффективности комплексной терапии патологии шейки матки, ассоциированной с папилломавирусной инфекцией / Т. Ю. Пестрикова, В. А. Пушкарь // Гинекология. – 2015. – (4): 50–53. Режим доступа: https://gynecology.orscience.ru/2079-5831/article/view/28470Test.– Pestrikova T. Yu., Pushkar V. A. Evaluation of comprehensive treatment of cervical pathology associated with HPV. Gynecology. 2015; (4): 50–53. (In Russ.) Available at: https://gynecology.orscience.ru/2079-5831/article/view/28470Test.; Пестрикова Т. Ю. Оценка вирусной нагрузки у пациенток с ВПЧ-ассоциированным цервицитом в процессе комплексного лечения / Т. Ю. Пестрикова [и др.] // Гинекология. – 2017/ – (3): 45–48. Режим доступа: https://gynecology.orscience.ru/2079-5831/article/view/28623Test. – Pestrikova T. Yu., Panfilova Yu. O., Yurasova E. A., Kotelnikova A. V. Assessment of viral load in patients with HPV-associated cervicitis during the course of complex treatment. Gynecology. 2017; (3): 45–48. (In Russ.) Available at: https://gynecology.orscience.ru/2079-5831/article/view/28623Test.; Буданов П. В. Папилломавирусная инфекция человека: эффективность лечения инозином пранобексом / П. В. Буданов [и др.] // Гинекология. – 2015. – (6): 56–59. Режим доступа: https://gynecology.orscience.ru/2079-5831/article/view/28497Test. – Budanov P. V., Churganova A. A., Bakhtiiarov K. R., Strizhakov A. N. Human papillomavirus infection: the efficacy of treatment with inosine pranobex. Gynecology. 2015; (6): 56–59. (In Russ.) Available at: https://gynecology.orscience.ru/2079-5831/article/view/28497Test.; Григорьева И. Н. Противовирусное лечение в комплексной терапии эпителиальных дисплазий и преинвазивного рака шейки матки / И. Н. Григорьева [и др.] // Опухоли женской репродуктивной системы. – 2007. – (3): 54–57. Режим доступа: https://cyberleninka.ru/article/n/protivovirusnoe-lechenie-v-kompleksnoy-terapii-epitelialnyh-displaziy-i-preinvazivnogo-raka-sheyki-matkiTest. – Grigorieva I. N., Kedrova A. G., Glazkova O. A., Kuznetsov V. V., Gritsay A. N. Antiviral treatment in the complex therapy of epithelial dysplasia and preinvasive cervical cancer. Opuholi Zenskoj Reproduktivnoj Sistemy. 2007; (3): 54–57. (In Russ.) Available at: https://cyberleninka.ru/article/n/protivovirusnoe-lechenie-v-kompleksnoy-terapii-epitelialnyh-displaziy-i-preinvazivnogo-raka-sheyki-matkiTest.; Кедрова А. Г. Местное иммуносупрессивное поражение при персистенции вируса папилломы человека / А. Г. Кедрова // РМЖ. Мать и дитя. – 2017. – (26): 1971–1976. Режим доступа: https://www.rmj.ru/articles/ginekologiya/Mestnye_immunosupressornye_povreghdeniya_pri_persistencii_virusa_papillomy_chelovekaTest/. – Kedrova A. G. Local immunosuppressive damage in the human papilloma-virus persistence. Russian Journal of Woman and Child Health. 2017; (26): 1971–1976. (In Russ.) Available at: https://www.rmj.ru/articles/ginekologiya/Mestnye_immunosupressornye_povreghdeniya_pri_persistencii_virusa_papillomy_chelovekaTest/.; https://www.med-sovet.pro/jour/article/view/7093Test

الإتاحة: https://doi.org/10.21518/2079-701X-2022-16-16-2Test
https://doi.org/10.1016/j.jogoh.2022.102442Test
https://doi.org/10.3390/jcm10245777Test
https://doi.org/10.1097/MD.0000000000021005Test
https://doi.org/10.1080/08923973.2020.1765374Test
https://doi.org/10.1002/cam4.4634Test
https://doi.org/10.1007/s00404-021-06217-1Test
https://doi.org/10.3389/fcimb.2022.884272Test
https://doi.org/10.1111/jog.14931Test
https://doi.org/10.18565/aig.2018.3.122-128Test

المؤلفون: I. R. Gazizova, S. R. Zainullina, E. B. Martynova

المصدر: Oftalʹmologiâ, Vol 16, Iss 3, Pp 366-370 (2019)

مصطلحات موضوعية: первичная открытоугольная глаукома, биматопрост, простамиды, монотерапия простамидами, аддитивная терапия простамидами, Ophthalmology, RE1-994

وصف الملف: electronic resource

العلاقة: https://www.ophthalmojournal.com/opht/article/view/1016Test; https://doaj.org/toc/1816-5095Test; https://doaj.org/toc/2500-0845Test

الوصول الحر: https://doaj.org/article/b033ba4f761d465e8fe0854d109acb6aTest

المؤلفون: T. Pushkar N., A. Azhigova M., P. Vlasov N., A. Kozhokaru B., Т. Пушкарь Н., А. Ажигова М., П. Власов Н., А. Кожокару Б.

المصدر: Neurology, Neuropsychiatry, Psychosomatics; Vol 13, No 3 (2021); 67-74 ; Неврология, нейропсихиатрия, психосоматика; Vol 13, No 3 (2021); 67-74 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2021-3

مصطلحات موضوعية: oxcarbazepine, AED monotherapy, focal epilepsy, epileptiform activity index, epilepsy biomarkers, окскарбазепин, монотерапия окскарбазепином, противоэпилептические препараты, фокальная эпилепсия, индекс эпилептиформной активности, биомаркеры эпилепсии

وصف الملف: application/pdf

العلاقة: https://nnp.ima-press.net/nnp/article/view/1576/1250Test; Annegers JF, Dubinsky S, Coan SP, et al. The incidence of epilepsy and unprovoked seizures in multiethnic, urban health maintenance organizations. Epilepsia. 1999 Apr;40(4):502-6. doi:10.1111/j.1528-1157.1999.tb00748.x; Hirtz D, Thurman DJ, Gwinn-Hardy K, et al. How common are the «common» neurologic disorders? Neurology. 2007 Jan 30;68(5):326-37. doi:10.1212/01.wnl.0000252807.38124.a3; Sander JW, Shorvon SD. Epidemiology of the epilepsies. J Neurol Neurosurg Psychiatry. 1996 Nov;61(5):433-43. doi:10.1136/jnnp.61.5.433; Карлов ВА. Эпилепсия у детей и взрослых женщин и мужчин. Москва: Бином; 2019.; Kalilani L, Sun X, Pelgrims B, et al. The epidemiology of drug-resistant epilepsy: A systematic review and meta-analysis. Epilepsia. 2018 Dec;59(12):2179-93. doi:10.1111/epi.14596. Epub 2018 Nov 13.; Kwan P, Brodie MJ. Epilepsy after the first drug fails: substitution or add-on? Seizure. 2000 Oct;9(7):464-8. doi:10.1053/seiz.2000.0442; Glauser T, Ben-Menachem E, Bourgeois B, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2013 Mar;54(3):551- 63. doi:10.1111/epi.12074. Epub 2013 Jan 25.; Santulli L, Coppola A, Balestrini S, Striano S. The challenges of treating epilepsy with 25 antiepileptic drugs. Pharmacol Res. 2016 May;107:211-9. doi:10.1016/j.phrs.2016.03.016. Epub 2016 Mar 16.; Белоусова ЕД, Мухин КЮ, Ермоленко НА и др. Эффективность и безопасность монотерапии трилепталом (окскарбазепин) у детей и подростков. Журнал неврологии и психиатрии им. C.C. Корсакова. 2010;110(5):45-50.; Geng H, Wang C. Efficacy and safety of oxcarbazepine in the treatment of children with epilepsy: a meta-analysis of randomized controlled trials. Neuropsychiatr Dis Treat. 2017 Mar 2;13:685-95. doi:10.2147/NDT.S130269. eCollection 2017.; Мухин КЮ, Пылаева ОА, Бородин РА, Мухина ЛН. Сравнительная эффективность и переносимость монотерапии Депакином хроносфера, препаратами группы карбамазепина пролонгированного действия и окскарбазепином при симптоматической и криптогенной фокальной эпилепсии (Исследование института детской неврологии и эпилепсии им. Святителя Луки). Русский журнал детской неврологии. 2015;10(1):4-15.; Петрухин АС, Воронкова КВ, Белоусова ЕД и др. Оценка эффективности, переносимости и безопасности монотерапии Трилепталом у детей с фокальными формами эпилепсии. Проспективное открытое многоцентровое 24-недельное исследование. Русский журнал детской неврологии. 2009;4(1):14-25.; Бурд СГ, Глухова ЛЮ, Бадалян ОЛ. Изучение эффективности и безопасности моно- и комбинированной терапии эпилепсии окскарбазепином у взрослых. Журнал неврологии и психиатрии им. C.C. Корсакова. 2010;110(6):66-9.; Зенков ЛР. Роль окскарбазепина в терапии эпилепсии. Consilium medicum. 2005;7(8):710-4.; Kanner AM, Ashman E, Gloss D, et al. Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs II: Treatment-resistant epilepsy: Report of the American Epilepsy Society and the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Epilepsy Curr. Jul-Aug 2018;18(4):269-78. doi:10.5698/1535-7597.18.4.269; Власов ПН, Молочкова ВВ. Применение окскарбазепина (трилептал) у молодых женщин, страдающих эпилепсией. Журнал неврологии и психиатрии им. С.С. Корсакова. 2009;(6):72-5.; Fisher RS, Acevedo C, Arzimanoglou A, et al. A practical clinical definition of epilepsy. Epilepsia. 2014 Apr;55(4):475-82. doi:10.1111/epi.12550. Epub 2014 Apr 14.; Uijl SG, Uiterwaal CSMP, Aldenkamp AP, et al. A cross-sectional study of subjective complaints in patients with epilepsy who seem to be well-controlled with anti-epileptic drugs. Seizure. 2006 Jun;15(4):242-8. doi:10.1016/j.seizure.2006.02.009. Epub 2006 Mar 23.; Marson AG, Appleton R, Baker GA, et al. A randomised controlled trial examining the longer-term outcomes of standard versus new antiepileptic drugs. The SANAD trial. Health Technol Assess. 2007 Oct;11(37):iii-iv, ix-x, 1- 134. doi:10.3310/hta11370; Koch MW, Polman SKL. Oxcarbazepine versus carbamazepine monotherapy for partial onset seizures. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD006453. doi:10.1002/14651858.CD006453.pub2; Schachter SC, Vazquez B, Fisher RS, et al. Oxcarbazepine: double-blind randomized, placebo-controlled, monotherapy trial for partial seizures. Neurology. 1999 Mar 10;52(4):732-7. doi:10.1212/wnl.52.4.732; French JA, Baroldi P, Brittain ST, Johnson JK. Efficacy and safety of extendedrelease oxcarbazepine (Oxtellar XRTM) as adjunctive therapy in patients with refractory partial-onset seizures: a randomized controlled trial. Acta Neurol Scand. 2014 Mar;129(3):143- 53. doi:10.1111/ane.12207. Epub 2013 Dec 21.; Bill PA, Vigonius U, Pohlmann H, et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res. 1997 Jun;27(3):195-204. doi:10.1016/s0920-1211(97)00024-7; Christe W, Kramer G, Vigonius U, et al. A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res. 1997 Mar;26(3):451-60. doi:10.1016/s0920-1211(96)01013-3; Bonnett L, Smith CT, Smith D, et al. Prognostic Factors for Time to Treatment Failure and Time to 12 Months of Remission for Patients With Focal Epilepsy: Post-Hoc, Subgroup Analyses of Data From the SANAD Trial. Lancet Neurol. 2012 Apr;11(4):331-40. doi:10.1016/S1474-4422(12)70018-2. Epub 2012 Feb 28.; Pauletto G, Bergonzi P. Oxcarbazepine reduces seizure frequency in a high proportion of patients with both newly diagnosed and refractory partial seizures in clinical practice. Seizure. 2006 Apr;15(3):150-5. doi:10.1016/j.seizure.2005.12.008. Epub 2006 Jan 24.; Martinez W, Ingenito A, Blakeslee M, et al. Efficacy, safety, and tolerability of oxcarbazepine monotherapy. Epilepsy Behav. 2006 Nov;9(3):448-56. doi:10.1016/j.yebeh.2006.04.022. Epub 2006 Sep 7.; Dogan EA, Usta BE, Bilgen R, et al. Efficacy, tolerability, and side effects of oxcarbazepine monotherapy: a prospective study in adult and elderly patients with newly diagnosed partial epilepsy. Epilepsy Behav. 2008 Jul;13(1):156-61. doi:10.1016/j.yebeh.2008.02.001. Epub 2008 Mar 10.; Novartis. Oxcarbazepine. Data on file. Basle; 1998.; Berghuis B, van der Palen J, de Haan G-J, et al. Carbamazepine- and oxcarbazepineinduced hyponatremia in people with epilepsy. Epilepsia. 2017 Jul;58(7):1227-33. doi:10.1111/epi.13777. Epub 2017 May 24.; https://nnp.ima-press.net/nnp/article/view/1576Test

الإتاحة: https://doi.org/10.14412/2074-2711-2021-3-67-74Test
https://doi.org/10.14412/2074-2711-2021-3Test
https://doi.org/10.1111/j.1528-1157.1999.tb00748.xTest
https://doi.org/10.1136/jnnp.61.5.433Test
https://doi.org/10.1111/epi.14596Test
https://doi.org/10.1111/epi.12074Test
https://doi.org/10.1016/j.phrs.2016.03.016Test
https://doi.org/10.2147/NDT.S130269Test
https://doi.org/10.5698/1535-7597.18.4.269Test
https://doi.org/10.1111/epi.12550Test

المؤلفون: Дубатова Ирина Владимировна, Irina V. Dubatova, Анцыборов Лёма Андреевич, Lema A. Antsyborov, Хейгетян Артур Федорович, Artur F. Kheigetian, Анцыборов Андрей Викторович, Andrey V. Antsyborov

المساهمون: Исследование не имело финансовой поддержки

المصدر: Interactive science; № 10(65); 9-24 ; Интерактивная наука; № 10(65); 9-24 ; ISSN: 2414-9411 ; 2414-9411 ; ISSN(electronic Version): 2500-2686 ; 2500-2686

مصطلحات موضوعية: дофамин, schizophrenic spectrum disorders, polypharmacy, monotherapy, dopamine, glutamate, serotonin, antipsychotics, расстройства шизофренического спектра, полифармация, монотерапия, глутамат, серотонин, антипсихотические препараты

وصف الملف: text/html

العلاقة: info:eu-repo/semantics/altIdentifier/pissn/2414-9411; info:eu-repo/semantics/altIdentifier/eissn/2500-2686; Monthly international scientific journal Interactive science Issue 10(65); https://interactive-plus.ru/e-articles/797/Action797-555399.pdfTest; Kondej M., Stępnicki P., Kaczor A. A. Multi-target approach for drug discovery against schizophrenia //International journal of molecular sciences. – 2018. -Vol. 19. – №. 10. -p. 3105; Alberca L. N., Talevi A. The Efficiency of Multi-target Drugs: A Network Approach //Approaching Complex Diseases. – 2020. -Vol. 3. -p. 63; Potkin S. G. et al. The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research //NPJ schizophrenia. – 2020. -Vol. 6. – №. 1. -p. 1–10; Campana M. et al. Characteristics and definitions of ultra-treatment-resistant schizophrenia-A systematic review and meta-analysis //Schizophrenia Research. – 2021. -Vol. 228. -p. 218–226; Mørup M. F., Kymes S. M., Oudin Åström D. A modelling approach to estimate the prevalence of treatment-resistant schizophrenia in the United States //PloS one. – 2020. -Vol. 15. – №. 6. -p. e0234121; Marques T. R. et al. Adenosine A2A receptor in schizophrenia: an in vivo brain PET imaging study //Psychopharmacology. – 2021. -p. 1–7; Huefner J. C. et al. Patterns of psychotropic medication at admission for youth in residential care //Journal of Child and Family Studies. – 2017. – Vol. 26. – №. 1. -p. 317–328.; Turabian J. L. Polypharmacy is an indicator of bad practice and low quality in general medicine //J Qual Healthcare Eco. – 2019. -Vol. 2. – №. 4. -; Lähteenvuo M., Tiihonen J. Antipsychotic polypharmacy for the management of schizophrenia: evidence and recommendations //Drugs. – 2021. – Vol. 81. – №. 11. -p. 1273–1284; Chávez-Castillo M. et al. Depression as a neuroendocrine disorder: emerging neuropsychopharmacological approaches beyond monoamines //Advances in pharmacological sciences. – 2019. -Vol. 2019; Mishra R. K., Mishra A., Gupta A. Magic Shotgun Nature with Scattergun Approach of Curcumin Repurposing in Obsessive-compulsive disorder: A Novel Metaphysician of Drug Discovery //CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders). – 2021; Stępnicki P. et al. Multi-targeted drug design strategies for the treatment of schizophrenia //Expert Opinion on Drug Discovery. – 2021. -Vol. 16. – №. 1. -p. 101–114; Saenz-Méndez P., Eriksson L. A. Exploring polypharmacology in drug design //Rational Drug Design. – Humana Press, New York, NY, 2018. -p. 229–243; Meltzer H. Y., Gadaleta E. Contrasting Typical and Atypical Antipsychotic Drugs //Focus. – 2021. -Vol. 19. – №. 1. -p. 3–13; Tiihonen J. et al. Association of antipsychotic polypharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia //JAMA psychiatry. – 2019. -Vol. 76. – №. 5. -p. 499–507; Galling B. et al. Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis //World Psychiatry. – 2017. -Vol. 16. – №. 1. -p. 77–89; Mentzel T. Q. et al. Clozapine monotherapy as a treatment for antipsychotic-induced tardive dyskinesia: a meta-analysis //The Journal of clinical psychiatry. – 2018. -Vol. 79. – №. 6. -p. 0–0; Luo C. et al. Characteristics of White Matter Structural Networks in Chronic Schizophrenia Treated with Clozapine or Risperidone and Those Never Treated //International Journal of Neuropsychopharmacology. – 2020. -Vol. 23. – №. 12. -p. 799–810.; Limandri B. J. Clinical use of dopamine modulators as third-generation antipsychotic agents //Journal of psychosocial nursing and mental health services. – 2019. -Vol. 57. – №. 2. -p. 7–11; Orsolini L., De Berardis D., Volpe U. Up-to-date expert opinion on the safety of recently developed antipsychotics //Expert Opinion on Drug Safety. – 2020. -Vol. 19. – №. 8. -p. 981–998; Preda A., Shapiro B. B. A safety evaluation of aripiprazole in the treatment of schizophrenia //Expert Opinion on Drug Safety. – 2020. -Vol. 19. – №. 12. -p. 1529–1538; Fornaro M. et al. Brexpiprazole for treatment-resistant major depressive disorder //Expert opinion on pharmacotherapy. – 2019. -Vol. 20. – №. 16. -p. 1925–1933; Earley W. et al. Cariprazine treatment of bipolar depression: a randomized double-blind placebo-controlled phase 3 study //American Journal of Psychiatry. – 2019. -Vol. 176. – №. 6. -p. 439–448; Corponi F. et al. Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone //European Neuropsychopharmacology. – 2019. -Vol. 29. – №. 9. -p. 971–985; Calabrese F. et al. The role of dopamine D3 receptors in the mechanism of action of cariprazine //CNS spectrums. – 2020. -Vol. 25. – №. 3. -p. 343–351; Duric V. et al. Cariprazine exhibits anxiolytic and dopamine D3 receptor-dependent antidepressant effects in the chronic stress model //International Journal of neuropsychopharmacology. – 2017. -Vol. 20. – №. 10. -p. 788–796.; Campbell R. H. et al. Review of cariprazine in management of psychiatric illness //Mental Health Clinician. – 2017. -Vol. 7. – №. 5. -p. 221–229; Garnock-Jones K. P. Cariprazine: a review in schizophrenia //CNS drugs. – 2017. -Vol. 31. – №. 6. -p. 513–525; Tarland E. et al. Effects of 2-bromoterguride, a dopamine D 2 receptor partial agonist, on cognitive dysfunction and social aversion in rats //Psychopharmacology. – 2018. -Vol. 235. – №. 1. -p. 99–108; Kang T. et al. Prodrug Strategies in the CNS Drugs: Small Modification Makes Big Improvements //Current Topics in Medicinal Chemistry. – 2021.; Wang S. M. et al. Investigational dopamine antagonists for the treatment of schizophrenia //Expert opinion on investigational drugs. – 2017. -Vol. 26. – №. 6. -p. 687–698.; Page C. E., Coutellier L. Reducing inhibition: A promising new strategy for the treatment of schizophrenia //EBioMedicine. – 2018. -Vol. 35. -p. 25; Kantrowitz J. T. Targeting Serotonin 5-HT 2A Receptors to Better Treat Schizophrenia: Rationale and Current Approaches //CNS drugs. – 2020. – p. 1–13; Vinkers C. H. Antipsychotics with no dopamine receptor blockade; promise or hype? //Nederlands tijdschrift voor geneeskunde. – 2020. -Vol. 164.; Morrison P. D., Murray R. M. The antipsychotic landscape: dopamine and beyond //Therapeutic advances in psychopharmacology. – 2018. -Vol. 8. – №. 4. -p. 127–135; Trabanco A. A., Bartolomé J. M., Cid J. M. mGluR2 positive allosteric modulators: an updated patent review (2013–2018) //Expert opinion on therapeutic patents. – 2019. -Vol. 29. – №. 7. -p. 497–507; Nicoletti F. et al. Targeting mGlu receptors for optimization of antipsychotic activity and disease-modifying effect in schizophrenia //Frontiers in psychiatry. – 2019. -Vol. 10. -p. 49; Stansley B. J., Conn P. J. The therapeutic potential of metabotropic glutamate receptor modulation for schizophrenia //Current opinion in pharmacology. – 2018. -Vol. 38. -p. 31–36; Hellyer S. D. et al. Development of clickable photoaffinity ligands for metabotropic glutamate receptor 2 based on two positive allosteric modulators chemotypes //ACS chemical neuroscience. – 2020. -Vol. 11. – №. 11. -p. 1597–1609.; Marchi M. et al. Sarcosine as an add-on treatment to antipsychotic medication for people with schizophrenia: a systematic review and meta-analysis of randomized controlled trials //Expert Opinion on Drug Metabolism & Toxicology. – 2021. -Vol. 17. – №. 4. -p. 483–493; Koola M. M. Potential role of antipsychotic-galantamine-memantine combination in the treatment of positive, cognitive, and negative symptoms of schizophrenia //Molecular neuropsychiatry. – 2018. -Vol. 4. – №. 3. -p. 134–148; Wu Q., Huang J., Wu R. Drugs Based on NMDAR Hypofunction Hypothesis in Schizophrenia //Frontiers in Neuroscience. – 2021. -Vol. 15. -p. 362; Czobor P., Bitter I. Pharmacologic treatment of negative symptoms: focus on efficacy //Managing Negative Symptoms of Schizophrenia. – 2020. -p. 67; Aringhieri S. et al. Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences //Pharmacology & Therapeutics. – 2018. -Vol. 192. -p. 20–41; MacKay M. A. B. et al. D-Serine: potential therapeutic agent and/or biomarker in schizophrenia and depression? //Frontiers in psychiatry. – 2019. -Vol. 10. -p. 25; Kumar A. et al. Potential drug targets and treatment of schizophrenia //Inflammopharmacology. – 2017. -Vol. 25. – №. 3. -p. 277–292; Yohn S. E., Conn P. J. Positive allosteric modulation of M1 and M4 muscarinic receptors as potential therapeutic treatments for schizophrenia //Neuropharmacology. – 2018. -Vol. 136. -p. 438–448; Dean B., Scarr E. Muscarinic M1 and M4 receptors: Hypothesis driven drug development for schizophrenia //Psychiatry research. – 2020. -Vol. 288. -p. 112989; Park R., Kim S., Kim E. Relationship of Change in Plasma Clozapine/N-desmethylclozapine Ratio with Cognitive Performance in Patients with Schizophrenia //Psychiatry investigation. – 2020. -Vol. 17. – №. 11. -p. 1158; Costa-Dookhan K. A. et al. The clozapine to norclozapine ratio: a narrative review of the clinical utility to minimize metabolic risk and enhance clozapine efficacy //Expert opinion on drug safety. – 2020. -Vol. 19. – №. 1. -p. 43–57; Molins C. et al. Plasma ratio of clozapine to N-desmethylclozapine can predict cognitive performance in treatment-resistant psychotic patients //Psychiatry research. – 2017. -Vol. 258. -p. 153–157; Augustin M. et al. Effect of fluvoxamine augmentation and smoking on clozapine serum concentrations //Schizophrenia research. – 2019. -Vol. 210. -p. 143–148; Edinoff A. N. et al. Selective Serotonin Reuptake Inhibitors and Clozapine: Clinically Relevant Interactions and Considerations //Neurology International. – 2021. -Vol. 13. – №. 3. -p. 445–463; Smith R. L. et al. Correlation between serum concentrations of N-desmethylclozapine and granulocyte levels in patients with schizophrenia: a retrospective observational study //CNS drugs. – 2017. -Vol. 31. – №. 11. -p. 991–997; Nichols J. H. Neuroleptics //Principles of Forensic Toxicology. – Springer, Cham, 2020. -p. 511–522; Frampton J. E. Brexpiprazole: a review in schizophrenia //Drugs. – 2019. -Vol. 79. – №. 2. -p. 189–200; Fukuyama K., Okada M. Effects of Atypical Antipsychotics, Clozapine, Quetiapine and Brexpiprazole on Astroglial Transmission Associated with Connexin43 //International Journal of Molecular Sciences. – 2021. -Vol. 22. – №. 11. -p. 5623; Frankel J. S., Schwartz T. L. Brexpiprazole and cariprazine: distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole //Therapeutic advances in psychopharmacology. – 2017. -Vol. 7. – №. 1. -p. 29–41; Stummer L., Markovic M., Maroney M. Brexpiprazole in the treatment of schizophrenia and agitation in Alzheimer’s disease //Neurodegenerative Disease Management. – 2020. -Vol. 10. – №. 4. -p. 205–217; Kaar S. J. et al. Antipsychotics: mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology //Neuropharmacology. – 2020. -Vol. 172. -p. 107704; Mobed A. et al. Bioassay: A novel approach in antipsychotic pharmacology //Clinica Chimica Acta. – 2020. -Vol. 509. -p. 30–35; Ballard C. et al. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study //The Lancet Neurology. – 2018. -Vol. 17. – №. 3. -p. 213–222; Yunusa I., El Helou M. L., Alsahali S. Pimavanserin: a novel antipsychotic with potentials to address an unmet need of older adults with dementia-related psychosis //Frontiers in pharmacology. – 2020. -Vol. 11. -p. 87; Odland A. U., Kristensen J. L., Andreasen J. T. Investigating the role of 5-HT2A and 5-HT2C receptor activation in the effects of psilocybin, DOI, and citalopram on marble burying in mice //Behavioural Brain Research. – 2021. -Vol. 401. -p. 113093; Nebuka M. et al. Behavioral characteristics of 5-HT2C receptor knockout mice: Locomotor activity, anxiety-, and fear memory-related behaviors //Behavioural brain research. – 2020. -Vol. 379. -p. 112394; Hrnjadovic A. et al. Effect of a 5-HT7 Receptor Antagonist on Reversal Learning in the Rat Attentional Set-Shifting Test //ACS Chemical Neuroscience. – 2020. -Vol. 12. – №. 1. -p. 42–48; Hopkins S. C. et al. Discovery of Non-racemic Amisulpride to Maximize Benefit/Risk of 5-HT7 and D2 Receptor Antagonism for the Treatment of Mood Disorders //Clinical Pharmacology & Therapeutics. – 2021; Castberg I. et al. Effects of age and gender on the serum levels of clozapine, olanzapine, risperidone, and quetiapine //Acta Psychiatrica Scandinavica. – 2017. -Vol. 136. – №. 5. -p. 455–464; Asenjo-Lobos C. et al. Clozapine versus risperidone for people with schizophrenia //The Cochrane Database of Systematic Reviews. – 2018. -Vol. 2018. – №. 12; Olotu U. Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia. – 2017; Patrichi B. et al. Antipsychotic polypharmacy in adult patients diagnosed with schizophrenia: A retrospective study //Experimental and Therapeutic Medicine. – 2021. -Vol. 22. – №. 5. -p. 1–6; Delgado A. et al. Clozapine in bipolar disorder: A systematic review and meta-analysis //Journal of psychiatric research. – 2020. -Vol. 125. -p. 21–27; Bioque M. et al. Clozapine and paliperidone palmitate antipsychotic combination in treatment-resistant schizophrenia and other psychotic disorders: A retrospective 6-month mirror-image study //European Psychiatry. – 2020. – Т. 63. – №. 1.; Lähteenvuo M., Tiihonen J. Antipsychotic polypharmacy for the management of schizophrenia: evidence and recommendations //Drugs. – 2021. -Vol. 81. – №. 11. -p. 1273–1284; Meftah A. M. et al. New discoveries for an old drug: a review of recent olanzapine research //Postgraduate medicine. – 2020. -Vol. 132. – №. 1. – p. 80–90; Yang L., Qi X. Effect of olanzapine combined with risperidone in the treatment of schizophrenia and its influence on cognitive function //Pakistan Journal of Medical Sciences. – 2021. -Vol. 37. – №. 3. -p. 646; Wang N. et al. Paroxetine combined with olanzapine in the treatment of schizophrenia //Pakistan journal of medical sciences. – 2020. -Vol. 36. – №. 3. -p. 516; Smith R. L. et al. Impact of antipsychotic polypharmacy on nonadherence of oral antipsychotic drugs-A study based on blood sample analyses from 24,239 patients //European Neuropsychopharmacology. – 2020. -Vol. 37. -p. 64–69; Lin S. K. Antipsychotic Polypharmacy: A dirty little secret or a fashion? //International Journal of Neuropsychopharmacology. – 2020. -Vol. 23. – №. 2. -p. 125–131; Jovanović M., Vučićević K., Miljković B. Understanding variability in the pharmacokinetics of atypical antipsychotics-focus on clozapine, olanzapine and aripiprazole population models //Drug metabolism reviews. – 2020. -Vol. 52. – №. 1. -p. 1–18; Baandrup L. Polypharmacy in schizophrenia //Basic & clinical pharmacology & toxicology. – 2020. -Vol. 126. – №. 3. -p. 183–192; Foster A., King J. Antipsychotic polypharmacy //Focus. – 2020. -Vol. 18. – №. 4. -p. 375–385; Naguy A., Al-Enezi N. Lamotrigine uses in psychiatric practice //American journal of therapeutics. – 2019. -Vol. 26. – №. 1. -p. e96-e102; Douglas-Hall P. et al. Variation in dose and plasma level of lamotrigine in patients discharged from a mental health trust //Therapeutic advances in psychopharmacology. – 2017. -Vol. 7. – №. 1. -p. 17–24; Crawford M. J. et al. Lamotrigine for people with borderline personality disorder: a RCT //Health Technology Assessment (Winchester, England). – 2018. -Vol. 22. – №. 17. -p. 1–68; Zheng W. et al. Clozapine augmentation with antiepileptic drugs for treatment-resistant schizophrenia: a meta-analysis of randomized controlled trials //The Journal of clinical psychiatry. – 2017. -Vol. 78. – №. 5. -p. 0–0.; Lee E. E. et al. Late-onset schizophrenia. – 2020; Talbot P. S. Anticonvulsants 12 Chapter for Mental Disorders: Valproate, Lamotrigine, Carbamazepine and Oxcarbazepine //Seminars in Clinical Psychopharmacology. – Cambridge University Press, 2020. -p. 362.; Khandelwal A., Mahajan C., Prabhakar H. Anti-epileptic Drugs (AEDs) //Pharmacology in Clinical Neurosciences. – Springer, Singapore, 2020. – p. 173–256; Goud Alladi C. et al. DNA methylation as a biomarker of treatment response variability in serious mental illnesses: a systematic review focused on bipolar disorder, schizophrenia, and major depressive disorder //International journal of molecular sciences. – 2018. -Vol. 19. – №. 10. -p. 3026.; Grover S., Sahoo S. Treatment of clozapine nonresponders //Current Treatment Options in Psychiatry. – 2019. -Vol. 6. – №. 1. -p. 32–63; Maan J. S., TvH D., Saadabadi A. Carbamazepine. – 2018; Okuma T. The discovery of the psychotropic effects of carbamazepine //The Psychopharmacologists III. – CRC Press, 2020. -p. 259–280; Chakrabarti S. Clozapine resistant schizophrenia: newer avenues of management //World Journal of Psychiatry. – 2021. -Vol. 11. – №. 8. -p. 429; Carboni L. et al. Biomarkers for response in major depression: comparing paroxetine and venlafaxine from two randomised placebo-controlled clinical studies //Translational psychiatry. – 2019. -Vol. 9. – №. 1. -p. 1–12; Kaur H. et al. Comparison of efficacy and tolerability of escitalopram and venlafaxine in treatment-naïve patients with unipolar nonpsychotic depression: Is there a need to revisit the prescription patterns? //Journal of Mental Health and Human Behaviour. – 2019. -Vol. 24. – №. 1. -p. 15; Gregory A., Mallikarjun P., Upthegrove R. Treatment of depression in schizophrenia: systematic review and meta-analysis //The British Journal of Psychiatry. – 2017. -Vol. 211. – №. 4. -p. 198–204; Bittner R. A. et al. Recent Developments in Treating Cognitive Impairment Associated with Schizophrenia. – 2021; Jones M. T., Strassnig M. T., Harvey P. D. Emerging 5-HT receptor antagonists for the treatment of Schizophrenia //Expert opinion on emerging drugs. – 2020. -Vol. 25. – №. 2. -p. 189–200; Căpățînă O. O., Micluția I. V., Fadgyas‑stănculete M. Current perspectives in treating negative symptoms of schizophrenia: A narrative review //Experimental and therapeutic medicine. – 2021. -Vol. 21. – №. 3. – p. 1–1; Yang A. C., Tsai S. J. New targets for schizophrenia treatment beyond the dopamine hypothesis //International journal of molecular sciences. – 2017. -Vol. 18. – №. 8. -p. 1689; Ng Q. X., Chong J. W. X., Chee K. T. Add-on pharmacotherapy for patients with first-episode schizophrenia: a clinical perspective //European Journal of Clinical Pharmacology. – 2021. -Vol. 77. – №. 6. -p. 931–932; Shafti S. S. Systematic Review of Local Studies Regarding Efficiency of Add-On Medications on Negative Symptoms of Schizophrenia: A Meta-Analysis //Current Psychopharmacology. – 2019. -Vol. 8. – №. 2. -p. 113–122.; Shafti S. S. Meta-analysis of Native Studies as Regards the Effectiveness of Antidepressants on Deficit Syndrome of Schizophrenia: A Systematic Review //Current Psychopharmacology. – 2017. -Vol. 6. – №. 2. – p. 148–157; Zaman H., Gibson R. C., Walcott G. Benzodiazepines for catatonia in people with schizophrenia or other serious mental illnesses //Cochrane Database of Systematic Reviews. – 2019. – №. 8; Hsu W. Y., Lane H. Y., Lin C. H. Medications used for cognitive enhancement in patients with schizophrenia, bipolar disorder, Alzheimer’s disease, and Parkinson’s disease //Frontiers in psychiatry. – 2018. -Vol. 9. -p. 91; Czarnecka K. et al. Memantine in neurological disorders-schizophrenia and depression //Journal of Molecular Medicine. – 2021. -p. 1–8; Martínez A. L. et al. Cognitive Deficit in Schizophrenia: From Etiology to Novel Treatments //International Journal of Molecular Sciences. – 2021. -Vol. 22. – №. 18. -p. 9905; Guercio G. D. et al. Improving cognitive training for schizophrenia using neuroplasticity enhancers: lessons from decades of basic and clinical research //Schizophrenia research. – 2019. -Vol. 207. -p. 80–92; Sheerin Fathima A. S. Neurocognition and Disability in Patients with Schizophrenia compared with Healthy Controls: дис. – PSG Institute of Medical Science and Research, Coimbatore, 2019; Sinkeviciute I. et al. Efficacy of different types of cognitive enhancers for patients with schizophrenia: a meta-analysis //NPJ schizophrenia. – 2018. -Vol. 4. – №. 1. -p. 1–14; Junho B. T., de Oliveira V. F. The role of NMDA receptor antagonists, amantadine and memantine, in schizophrenia treatment: a systematic review //Archives of Clinical Psychiatry (São Paulo). – 2019. -Vol. 46. -p. 165–168; Zheng W. et al. Adjunctive memantine for major mental disorders: A systematic review and meta-analysis of randomized double-blind controlled trials //Schizophrenia research. – 2019. -Vol. 209. -p. 12–21; Koola M. M., Praharaj S. K., Pillai A. Galantamine-memantine combination as an antioxidant treatment for schizophrenia //Current behavioral neuroscience reports. – 2019. -Vol. 6. – №. 2. -p. 37–50; Iqbal M. N., Levin C. J., Levin F. R. Treatment for substance use disorder with co-occurring mental illness //FOCUS, A Journal of the American Psychiatric Association. – 2019. -Vol. 17. – №. 2. -p. 88–97; Li K. J., Chen A., DeLisi L. E. Opioid use and schizophrenia //Current opinion in psychiatry. – 2020. -Vol. 33. – №. 3. -p. 219–224; Bennett M. E., Bradshaw K. R., Catalano L. T. Treatment of substance use disorders in schizophrenia //The American journal of drug and alcohol abuse. – 2017. -Vol. 43. – №. 4. -p. 377–390; Pourshams M. et al. The Evaluation of Atypical Antipsychotic Augmentation with Atomoxetine in the Reduction of Negative Symptoms in Patients with Schizophrenia: A Randomized, Double-blind, Placebo-Controlled Clinical Trial //Clinical Schizophrenia & Related Psychoses. – 2020. -Vol. 14. – №. 2. -p. 54–57; Robbins T. W. Pharmacological treatment of cognitive deficits in nondementing mental health disorders //Dialogues in clinical neuroscience. – 2019. -Vol. 21. – №. 3. -p. 301; Giakoumatos C. I., Osser D. The psychopharmacology algorithm project at the Harvard south shore program: an update on unipolar nonpsychotic depression //Harvard review of psychiatry. – 2019. -Vol. 27. – №. 1. -p. 33–52; Ciruela F. et al. The adenosinergic system in the neurobiology of schizophrenia: Prospective adenosine receptor-based pharmacotherapy //Psychiatry and Neuroscience Update-Vol. II. – Springer, Cham, 2017. -p. 405–419.; Beggiato S. et al. Adenosine and Kynurenic Acid Interactions: Possible Relevance for Schizophrenia Treatment? //Frontiers in Pharmacology. – 2021. -Vol. 12; Cheffer A. et al. Purinergic system in psychiatric diseases //Molecular psychiatry. – 2018. -Vol. 23. – №. 1. -p. 94–106; Gadelha A. et al. Is adenosine associated with sudden death in schizophrenia? A new framework linking the adenosine pathway to risk of sudden death //Neuroscience & Biobehavioral Reviews. – 2018. -Vol. 84. -p. 29–34; Behmanesh H. et al. Risperidone combination therapy with propentofylline for treatment of irritability in autism spectrum disorders: a randomized, double-blind, placebo-controlled clinical trial //Clinical neuropharmacology. – 2019. -Vol. 42. – №. 6. -p. 189–196; Lago S. G., Bahn S. Clinical trials and therapeutic rationale for drug repurposing in schizophrenia //ACS chemical neuroscience. – 2018. -Vol. 10. – №. 1. -p. 58–78; Deguil J., Bordet R. Contributions of animal models of cognitive disorders to neuropsychopharmacology //Therapies. – 2021. -Vol. 76. – №. 2. -p. 87–99; Lintunen J. et al. Adenosine modulators and calcium channel blockers as add-on treatment for schizophrenia //NPJ schizophrenia. – 2021. -Vol. 7. – №. 1. -p. 1–7; Chen A. T., Malmstrom T., Nasrallah H. A. Allopurinol augmentation in acute mania: a meta-analysis of placebo-controlled trials //Journal of affective disorders. – 2018. -Vol. 226. -p. 245–250; Berry T., Abohamza E., Moustafa A. A. Treatment-resistant schizophrenia: Focus on the transsulfuration pathway //Reviews in the Neurosciences. – 2020. -Vol. 31. – №. 2. -p. 219–232; Shalbafan M. et al. The role of celecoxib in treatment of psychiatric disorders: A review article //J. Neurol. Psychol. – 2018. -Vol. 6. – №. 4; Kotecha A., Upthegrove R. Celecoxib plus standard care for people with schizophrenia //The Cochrane Database of Systematic Reviews. – 2018. -Vol. 2018. – №. 12.; Hong J., Bang M. Anti-inflammatory strategies for schizophrenia: a review of evidence for therapeutic applications and drug repurposing //Clinical Psychopharmacology and Neuroscience. – 2020. -Vol. 18. – №. 1. -p. 10; Cho M. et al. Adjunctive use of anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials //Australian & New Zealand Journal of Psychiatry. – 2019. -Vol. 53. – №. 8. -p. 742–759; Fond G. et al. The role of inflammation in the treatment of schizophrenia //Frontiers in psychiatry. – 2020. -Vol. 11. -p. 160; Faridhosseini F. et al. Celecoxib added to mood stabilizer for treating acute mania: A randomized, double-blind, placebo-controlled trial. – 2020; McGregor C., Riordan A., Thornton J. Estrogens and the cognitive symptoms of schizophrenia: Possible neuroprotective mechanisms //Frontiers in neuroendocrinology. – 2017. -Vol. 47. -p. 19–33; Brzezinski-Sinai N. A., Brzezinski A. Schizophrenia and sex hormones: what is the link? //Frontiers in Psychiatry. – 2020. -Vol. 11; Brand B. A., de Boer J. N., Sommer I. E. C. Estrogens in schizophrenia: progress, current challenges and opportunities //Current opinion in psychiatry. – 2021. -Vol. 34. – №. 3. -p. 228; de Boer J. et al. The effect of raloxifene augmentation in men and women with a schizophrenia spectrum disorder: a systematic review and meta-analysis //npj Schizophrenia. – 2018. -Vol. 4. – №. 1. -p. 1–6; Fernando P., Sommer I. E. C., Hasan A. Do we need sex-oriented clinical practice guidelines for the treatment of schizophrenia? //Current opinion in psychiatry. – 2020. -Vol. 33. – №. 3. -p. 192–199; Riecher-Rössler A., Butler S., Kulkarni J. Sex and gender differences in schizophrenic psychoses-a critical review //Archives of women's mental health. – 2018. -Vol. 21. – №. 6. -p. 627–648; Searles S., Makarewicz J. A., Dumas J. A. The role of estradiol in schizophrenia diagnosis and symptoms in postmenopausal women //Schizophrenia research. – 2018. -Vol. 196. -p. 35–38; Lascurain M. B. et al. Improvement in depression with estrogen treatment in women with schizophrenia //Archives of women's mental health. – 2020. -Vol. 23. – №. 2. -p. 149–154; Lombardo G. et al. Baseline cortisol and the efficacy of antiglucocorticoid treatment in mood disorders: A meta-analysis //Psychoneuroendocrinology. – 2019. -Vol. 110. -p. 104420; Soria V. et al. Targeting hypothalamic-pituitary-adrenal axis hormones and sex steroids for improving cognition in major mood disorders and schizophrenia: a systematic review and narrative synthesis //Psychoneuroendocrinology. – 2018. -Vol. 93. -p. 8–19; Woldesenbet Y. M. et al. The status of serum cortisol before and after treatment of schizophrenia and its correlation to disease severity and improvement: A longitudinal study //SAGE open medicine. – 2021. -Vol. 9. -p. 20503121211056216; Fujii Y. et al. Cushing's syndrome and psychosis: a case report and literature review //The primary care companion for CNS disorders. – 2018. -Vol. 20. – №. 5. -p. 0–0; Mikulska J. et al. HPA Axis in the Pathomechanism of Depression and Schizophrenia: New Therapeutic Strategies Based on Its Participation //Brain Sciences. – 2021. -Vol. 11. – №. 10. -p. 1298; Labad J. The role of cortisol and prolactin in the pathogenesis and clinical expression of psychotic disorders //Psychoneuroendocrinology. – 2019. -Vol. 102. -p. 24–36; Yates C. et al. Modulating Neuroplasticity: Lessons Learned from Antidepressants and Emerging Novel Therapeutics //Current Treatment Options in Psychiatry. – 2021. -p. 1–29; Wagner E. et al. Clozapine augmentation strategies-a systematic meta-review of available evidence. Treatment options for clozapine resistance //Journal of Psychopharmacology. – 2019. – Т. 33. – №. 4. – С. 423–435; Ceskova E., Silhan P. Novel treatment options in depression and psychosis //Neuropsychiatric disease and treatment. – 2018. -Vol. 14. -p. 741; Haddad P. M., Correll C. U. The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses //Therapeutic advances in psychopharmacology. – 2018. -Vol. 8. – №. 11. -p. 303–318; Schwartz M. D. et al. Trace amine-associated receptor 1: a multimodal therapeutic target for neuropsychiatric diseases //Expert opinion on therapeutic targets. – 2018. -Vol. 22. – №. 6. -p. 513–526; Dodd S. et al. Trace Amine-Associated Receptor 1 (TAAR1): A new drug target for psychiatry? //Neuroscience & Biobehavioral Reviews. – 2021. -Vol. 120. -p. 537–541; Girgis R. R. et al. The past and future of novel, non-dopamine-2 receptor therapeutics for schizophrenia: a critical and comprehensive review //Journal of psychiatric research. – 2019. -Vol. 108. -p. 57–83; Kirkpatrick B., Kennedy B. K. Accelerated aging in schizophrenia and related disorders: Future research //Schizophrenia research. – 2018. -Vol. 196. -p. 4–8; Luykx J. J. et al. In the aftermath of clozapine discontinuation: comparative effectiveness and safety of antipsychotics in patients with schizophrenia who discontinue clozapine //The British Journal of Psychiatry. – 2020. -Vol. 217. – №. 3. -p. 498–505; Siskind D. J. et al. Augmentation strategies for clozapine refractory schizophrenia: a systematic review and meta-analysis //Australian & New Zealand Journal of Psychiatry. – 2018. -Vol. 52. – №. 8. -p. 751–767; Harvey P. D., Sand M. Pharmacological augmentation of psychosocial and remediation training efforts in schizophrenia //Frontiers in psychiatry. – 2017. -Vol. 8. -p. 177; Galling B. et al. Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia //Acta Psychiatrica Scandinavica. – 2018. -Vol. 137. – №. 3. -p. 187–205; Nimgaonkar V. L. et al. The complement system: a gateway to gene-environment interactions in schizophrenia pathogenesis //Molecular psychiatry. – 2017. -Vol. 22. – №. 11. -p. 1554–1561; Yu H. et al. Five novel loci associated with antipsychotic treatment response in patients with schizophrenia: a genome-wide association study //The Lancet Psychiatry. – 2018. -Vol. 5. – №. 4. -p. 327–338; https://interactive-plus.ru/files/Books/6204bd59475d0.jpeg?req=555399Test; https://interactive-science.media/article/555399/discussion_platformTest; https://doi.org/10.21661/r-555399Test

الإتاحة: https://doi.org/10.21661/r-555399Test
https://interactive-plus.ru/files/Books/6204bd59475d0.jpeg?req=555399Test
https://interactive-science.media/article/555399/discussion_platformTest

المؤلفون: I. Volkov V., G. Karpovich S., A. Kalina V., O. Volkova K., И. Волков В., Г. Карпович С., А. Калина В., О. Волкова К.

المساهمون: Публикация статьи поддержана ООО «Бауш Хелс».

المصدر: Neurology, Neuropsychiatry, Psychosomatics; Vol 12, No 1 (2020); 50-55 ; Неврология, нейропсихиатрия, психосоматика; Vol 12, No 1 (2020); 50-55 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2020-1

مصطلحات موضوعية: genetic generalized epilepsy, monotherapy, polytherapy, gender characteristics, генетическая генерализованная эпилепсия, монотерапия, политерапия, гендерные особенности

وصف الملف: application/pdf

العلاقة: https://nnp.ima-press.net/nnp/article/view/1261/998Test; Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia. 2010 Apr; 51(4):676-85. doi:10.1111/j.1528-1167.2010.02522.x. Epub 2010 Feb 26.; Tomson T, Marson A, Boon P, et al. Valproate in the treatment of epilepsy in women and girls. Pre-Publication Summary of Recommendations from a joint Task Force of ILAE-Commission on European Affairs and European Academy of Neurology (EAN). 2015. https://www.eaneurology.org/fileadmin/_migrated/content_uploads/ValproateCommentILAE-0315.pdfTest; Мухин КЮ, Петрухин АС. Идиопатические формы эпилепсии: систематика, диагностика, терапия. Москва: Арт-БизнесЦентр; 2000. 19 c.; Callaghan B, Schlesinger M, Rodemer W, et al. Remission and relapse in a drug-resistant epilepsy population followed prospectively. Epilepsia. 2011 Mar;52(3):619-26. doi:10.1111/j.1528-1167.2010.02929.x. Epub 2011 Jan 26.; Benbadis SR. Practical management issues for idiopathic generalized epilepsies. Epilepsia. 2005;46 Suppl 9:125-32.; Coppola G, Auricchio G, Federico R, et al. Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomized, parallel-group study. Epilepsia. 2004 Sep; 45(9):1049-53.; Guerrini R, Dravet C, Genton P, et al. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia. 1998 May;39(5): 508-12.; Crespel A, Genton P, Berramdane M, et al. Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies. Neurology. 2005 Sep 13;65(5):762-4.; Covanis A. Childhood absence epilepsy. In: Panayiotopoulos CP, editor. Atlas of epilepsies. London: Springer-Verlag; 2010. P. 1013-23.; Cavitt J, Privitera M. Levetiracetam induces a rapid and sustained reduction of generalized spike-wave and clinical absence. Arch Neurol. 2004 Oct;61(10):1604-7.; Yacubian EM, de Araujo Filho GM. Management issues for patients with idiopathic generalized epilepsies. Epileptology. 2013 Mar; 1(1):1-10.; French JA, Krauss GL, Wechsler RT, et al. Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy A randomized trial. Neurology. 2015 Sep 15;85(11):950-7.; Gesche J, Khanevski M, Solberg C, et al. Resistance to valproic acid as predictor of treatment resistance in genetic generalized epilepsies. Epilepsia. 2017 Apr;58(4):e64-e69. doi:10.1111/epi.13702. Epub 2017 Feb 23.; Карлов ВА, Гехт АБ, Гузева ВИ и др. Алгоритмы моно- и политерапии в клинической эпилептологии. Часть 1. Общие принципы выбора фармакотерапии. Журнал неврологии и психиатрии им. С.С. Корсакова. 2016;116(6):109-14.; Власов ПН. Применение вальпроатов у женщин детородного возраста и беременных, страдающих эпилепсией. Неврология, нейропсихиатрия, психосоматика. 2015; 7(1S):4-9. doi:10.14412/2074-2711-2015-1S-4-9; Nevitt SJ, Sudell M, Weston J, et al. Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. Cochrane Database Syst Rev. 2017 Dec 15;12:CD011412. doi:10.1002/14651858.CD011412.pub3.; Власов ПН. Применение вальпроата и карбамазепина в терапии эпилепсии (в помощь практическому врачу). Неврология, нейропсихиатрия, психосоматика. 2018; 10 (4):129-38. doi:10.14412/2074-2711-2018-4-129-138; Карлов ВА, Андреева ОВ. Применение инъекционного депакина при лечении эпилептического статуса. Русский медицинский журнал. 2001;20(9):889-93.; Shorvon SD. Oxford Textbook of Epilepsy and Epileptic Seizures. Oxford University Press; 2010.; Kwan P, Brodie MJ. Epilepsy after the first drug fails: substitution or add-on? Seizure. 2000 Oct;9(7):464-8.; Deckers CL, Hekster YA, Keyser A, et al. Monotherapy versus polytherapy for epilepsy: a multicenter double-blind randomized study. Epilepsia. 2001 Nov;42(11):1387-94.; Millul A, Iudice A, Adami M, et al. Alternative monotherapy or add-on therapy in patients with epilepsy whose seizures do not respond to the first monotherapy: an Italian multicenter prospective observational study. Epilepsy Behav. 2013 Sep;28(3):494-500. doi:10.1016/j.yebeh.2013.05.038. Epub 2013 Jul 26.; https://nnp.ima-press.net/nnp/article/view/1261Test

الإتاحة: https://doi.org/10.14412/2074-2711-2020-1-50-55Test
https://doi.org/10.14412/2074-2711-2020-1Test
https://doi.org/10.1111/j.1528-1167.2010.02522.xTest
https://doi.org/10.1111/j.1528-1167.2010.02929.xTest
https://doi.org/10.1111/epi.13702Test
https://doi.org/10.14412/2074-2711-2015-1S-4-9Test
https://doi.org/10.1002/14651858.CD011412.pub3Test
https://doi.org/10.14412/2074-2711-2018-4-129-138Test
https://doi.org/10.1016/j.yebeh.2013.05.038Test
https://nnp.ima-press.net/nnp/article/view/1261Test

المؤلفون: I. Samoylenko V., L. Demidov V., И. Самойленко В., Л. Демидов В.

المصدر: Meditsinskiy sovet = Medical Council; № 9 (2020); 80-93 ; Медицинский Совет; № 9 (2020); 80-93 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: metastatic melanoma, prognosis, biomarkers, first line of therapy, combined immunotherapy, monotherapy with immune checkpoints blockers, combined targeting therapy, triple combination of BRAFi + MEKi + aPDL1, reversion to previous therapy (re-challenge), метастатическая меланома, прогноз, биомаркеры, первая линия терапии, комбинированная иммунотерапия, монотерапия блокаторами иммунных чек-пойнтов, комбинированная таргетная терапия, тройная комбинация BRAFi + MEKi + aPDL1, возврат к предыдущей терапии (ре-челлендж)

وصف الملف: application/pdf

العلاقة: https://www.med-sovet.pro/jour/article/view/5707/5205Test; Balch C.M., Gershenwald J.E., Soong S.J., Thompson J.F., Atkins M.B., Byrd D.R. et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199–6206. doi:10.1200/JCO.2009.23.4799.; Brierley J.D., Gospodarowicz M.K., Wittekind C. (eds.). TNM classification of malignant tumors. 8th ed. Oxford, UK: John Wiley & Sons, Inc; 2017.; Gershenwald J.E., Scolyer R.A., Hess K.R., Sondak V.K., Long G.V., Ross M.I. et al. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472–492. doi:10.3322/caac.21409.; Gastman B.R., Gerami P., Kurley S.J., Cook R.W., Leachman S., Vetto J.T. Identification of patients at risk of metastasis using a prognostic 31-gene expression profile in subpopulations of melanoma patients with favorable outcomes by standard criteria. J Am Acad Dermatol. 2019;80(1):149– 157. doi:10.1016/j.jaad.2018.07.028.; Dickson P.V., Gershenwald J.E. Staging and prognosis of cutaneous melanoma. Surg Oncol Clin N Am. 2011;20(1):1–17. doi:10.1016/j.soc.2010.09.007.; Tejera-Vaquerizo A., Barrera-Vigo M.V., Lopez-Navarro N., Herrera-Ceballos E. Growth rate as a prognostic factor in localized invasive cutaneous melanoma. J Eur Acad Dermatol Venereol. 2010;24(2):147–154. doi:10.1111/j.1468-3083.2009.03367.x.; Gualdi G., Panarese F., Meogrossi G., Marchioni M., De Tursi M., Di Marino P. et al. Speed Rate (SR) as a new dynamic index of melanoma behavior. Pigment Cell Melanoma Res. 2020. doi:10.1111/pcmr.12890.; Giuffrida R., Conforti C., Schmid K., Deinlein T., Zalaudek I. Rate of growthA novel surrogate marker for high-risk cutaneous squamous cell carcinoma? A case report and review of the literature. Dermatol Ther. 2020;33(1):e13156. doi:10.1111/dth.13156.; Menzer C., Menzies A.M., Carlino M.S., Reijers I., Groen E.J., Eigentler T. et al. Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations. J Clin Oncol. 2019;37(33):3142–3151. doi:10.1200/JCO.19.00489.; Richtig G., Hoeller C., Kashofer K., Aigelsreiter A., Heinemann A., Kwong L.N. et al. Beyond the BRAF(V)(600E) hotspot: biology and clinical implications of rare BRAF gene mutations in melanoma patients. Br J Dermatol. 2017;177(4):936–944. doi:10.1111/bjd.15436.; Long G.V., Menzies A.M., Nagrial A.M., Haydu L.E., Hamilton A.L., Mann G.J. et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol. 2011;29(10):1239–1246. doi:10.1200/JCO.2010.32.4327.; Hodi F.S., Corless C.L., Giobbie-Hurder A., Fletcher J.A., Zhu M., MarinoEnriquez A. et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol. 2013;31(26):3182–3190. doi:10.1200/JCO.2012.47.7836.; Dummer R., Schadendorf D., Ascierto P.A., Arance A., Dutriaux C., Di Giacomo A.M. et al. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18(4):435–445. doi:10.1016/S1470-2045(17)30180-8.; Larkin J., Chiarion-Sileni V., Gonzalez R., Grob J.J., Rutkowski P., Lao C.D. et al. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2019;381(16):1535–1546. doi:10.1056/NEJMoa1910836.; Prat A., Navarro A., Pare L., Reguart N., Galvan P., Pascual T. et al. ImmuneRelated Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma. Cancer Res. 2017;77(13):3540–3550. doi:10.1158/0008-5472.CAN-16-3556.; Patel S.P., Kurzrock R. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Mol Cancer Ther. 2015;14(4):847–856. doi:10.1158/1535-7163.MCT-14-0983.; Lee E.Y., Kulkarni R.P. Circulating biomarkers predictive of tumor response to cancer immunotherapy. Expert Rev Mol Diagn. 2019;19(10):895–904. doi:10.1080/14737159.2019.1659728.; Carlino M.S., Long G.V., Schadendorf D., Robert C., Ribas A., Richtig E. et al. Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial. Eur J Cancer. 2018;101:236–243. doi:10.1016/j.ejca.2018.06.034.; Lebbe C., Meyer N., Mortier L., Marquez-Rodas I., Robert C., Rutkowski P. et al. Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial. J Clin Oncol. 2019;37(11):867–875. doi:10.1200/JCO.18.01998.; Long G.V., Atkinson V., Cebon J.S., Jameson M.B., Fitzharris B.M., McNeil C.M. et al. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. Lancet Oncol. 2017;18(9):1202–1210. doi:10.1016/S1470-2045(17)30428-X.; Wolchok J.D., Chiarion-Sileni V., Gonzalez R., Rutkowski P., Grob J.J., Cowey C.L. et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2017;377(14):1345–1356. doi:10.1056/NEJMoa1709684.; Brower V. Hyperprogressive disease with anti-PD-1 and anti-PD-L1. Lancet Oncol. 2016;17(12):e527. doi:10.1016/S1470-2045(16)30590-3.; Champiat S., Dercle L., Ammari S., Massard C., Hollebecque A., Postel-Vinay S. et al. Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1. Clin Cancer Res. 2017;23(8):1920–1928. doi:10.1158/1078-0432.CCR-16-1741.; Самойленко И.В., Жуликов Я.И., Демидов Л.В. Феномен гиперпрогрессирования опухолей на фоне применения блокаторов PD1: мифы или реальность? Фарматека. 2018;(12):22–28. doi:10.18565/pharmateca.2018.12.22-28.; Robert C., Ribas A., Schachter J., Arance A., Grob J.J., Mortier L. et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019;20(9):1239– 1251. doi:10.1016/S1470-2045(19)30388-2.; Robert C., Larkin J., Ascierto P.A., Long G.V., Hassel J.C., Schadendorf D. et al. Characterization of complete responses (CRs) in patients with advanced melanoma (MEL) who received the combination of nivolumab (NIVO) and ipilimumab (IPI), NIVO or IPI alone. Ann Oncol. 2017;28:428–448. doi:10.1093/annonc/mdx377.; Larkin J., Chiarion-Sileni V., Gonzalez R., Grob J.J., Cowey C.L., Lao C.D. et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015;373(1):23–34. doi:10.1056/NEJMoa1504030.; Hamid O., Robert C., Daud A., Hodi F.S., Hwu W.-J., Kefford R. et al. 5-year survival outcomes in patients (pts) with advanced melanoma treated with pembrolizumab (pembro) in KEYNOTE-001. Journal of Clinical Oncology. 2018;36(15):9516. doi:10.1200/JCO.2018.36.15_suppl.9516.; Daud A., Gill J., Kamra S., Chen L., Ahuja A. Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients. J Hematol Oncol. 2017;10(1):3. doi:10.1186/s13045-016-0369-8.; Ascierto P.A., McArthur G.A., Dreno B., Atkinson V., Liszkay G., Di Giacomo A.M. et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)- mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016;17(9):1248–1260. doi:10.1016/S1470-2045(16)30122-X.; Robert C., Grob J.J., Stroyakovskiy D., Karaszewska B., Hauschild A., Levchenko E. et al. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. N Engl J Med. 2019;381(7):626–636. doi:10.1056/NEJMoa1904059.; McArthur G.A., Dréno B., Larkin J., Ribas A., Liszkay G., Maio M. et al. (eds.). 5­year survival update of cobimetinib plus vemurafenib BRAF V600 mutationpositive advanced melanoma: final analysis of the coBRIM study. 16th International Congress of the Society for Melanoma Research. Salt Lake City, UT, USA. 2019 November 20–23.; Ribas A., Daud A., Pavlick A.C., Gonzalez R., Lewis K.D., Hamid O. et al. Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma. Clin Cancer Res. 2020;26(1):46–53. doi:10.1158/1078-0432.CCR-18-4180.; Das Thakur M., Salangsang F., Landman A.S., Sellers W.R., Pryer N.K., Levesque M.P. et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature. 2013;494(7436):251–255. doi:10.1038/nature11814.; Dooley A.J., Gupta A., Bhattacharyya M., Middleton M.R. Intermittent dosing with vemurafenib in BRAF V600E-mutant melanoma: review of a case series. Ther Adv Med Oncol. 2014;6(6):262–266. doi:10.1177/1758834014548187.; Algazi A., Othus M., Daud A., Lo R., Mehnert J., Truong T.-G. et al. (eds.). SWOG S1320: Improved progression­free survival with continuous compared to intermittent dosing with dabrafenib and trametinib in patients with BRAF mutated melanoma. AACR Annual Meeting 2020. 2020 April 27. Virtual Meeting I.; Ascierto P.A., Ferrucci P.F., Stephens R., Del Vecchio M., Atkinson V., Schmidt H. et al. Keynote-022 part 3: phase 2 randomized study of 1l dabrafenib (d) and trametinib (t) plus pembrolizumab (pembro) or placebo (pbo) for BRAF-mutant advanced melanoma. Ann Oncol. 2018;29:442–466. doi:10.1093/annonc/mdy289.; McArthur G., Stroyakovskiy D., Gogas H., Robert C., Lewis K., Protsenko S. et al. (eds.). Evaluation of atezolizumab (A), cobimetinib (C), and vemurafenib (V) in previously untreated patients with BRAFV600 mutation­positive advanced melanoma: Primary results from the phase 3 IMspire150 trial. AACR Annual Meeting 2020. 2020 April 27. Virtual Annual Meeting I.; Kreft S., Gesierich A., Eigentler T., Franklin C., Valpione S., Ugurel S. et al. Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma. Eur J Cancer. 2019;116:207–215. doi:10.1016/j.ejca.2019.05.015.; Самойленко И.В., Жуликов Я.А., Харкевич Г.Ю., Петенко Н.Н., Демидов Л.В. Опыт применения ниволумаба в терапии предлеченных пациентов с метастатической меланомой кожи. Злокачественные опухоли. 2018;8(3):78–85. doi:10.18027/2224-5057-2018-8-3-78-85.; Johnson D.B., Pectasides E., Feld E., Ye F., Zhao S., Johnpulle R. et al. Sequencing Treatment in BRAFV600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition. J Immunother. 2017;40(1):31–35. doi:10.1097/CJI.0000000000000148.; Samoylenko I., Kharkevich G., Petenko N.N., Orlova K.V., Sinelnikov I., Utyashev I.A. et al. Paclitaxel and carboplatin chemotherapy in patients with metaststic melanoma refractory to BRAF/MEK inhibitors. Journal of Clinical Oncology. 2016;34(15):9552. doi:10.1200/JCO.2016.34.15_suppl.9552.; Valpione S., Carlino M.S., Mangana J., Mooradian M.J., McArthur G., Schadendorf D. et al. Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study. Eur J Cancer. 2018;91:116–124. doi:10.1016/j.ejca.2017.12.007.; Schreuer M., Jansen Y., Planken S., Chevolet I., Seremet T., Kruse V. et al. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF(V600)-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial. Lancet Oncol. 2017;18(4):464–472. doi:10.1016/S1470-2045(17)30171-7.; Amann V.C., Hoffmann D., Mangana J., Dummer R., Goldinger S.M. Successful retreatment with combined BRAF/MEK inhibition in metastatic BRAFV600-mutated melanoma. J Eur Acad Dermatol Venereol. 2017;31(10):1638–1640. doi:10.1111/jdv.14268.; Самойленко И.В., Жуликов Я.А., Демидов Л.В. Повторное применение ингибиторов BRAF и MEK у больных метастатической меланомой после прогрессирования на ингибиторах BRAF и МЕК. Обзор литературы и клиническое наблюдение. Медицинский совет. 2017;14(6):6–10. doi:10.21518/2079-701X-2017-14-6-10.; Desvignes C., Abi Rached H., Templier C., Drumez E., Lepesant P., Desmedt E. et al. BRAF inhibitor discontinuation and rechallenge in advanced melanoma patients with a complete initial treatment response. Melanoma Res. 2017;27(3):281–287. doi:10.1097/CMR.0000000000000350.; Carlino M.S., Vanella V., Girgis C., Giannarelli D., Guminski A., Festino L. et al. Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series. Br J Cancer. 2016;115(11):1280–1284. doi:10.1038/bjc.2016.321.; Vanhaecke C., Deilhes F., Chanal J., Regnier-Rosencher E., Boitier F., Boulinguez S. et al. BRAF V600 inhibitor discontinuation after complete response in advanced melanoma: a retrospective analysis of 16 patients. Br J Dermatol. 2017;177(4):94–95. doi:10.1111/bjd.15345.; Reschke R., Simon J.C., Ziemer M. Rechallenge of targeted therapy in metastatic melanoma. J Dtsch Dermatol Ges. 2019;17(5):483–486. doi:10.1111/ddg.13766.; Vinal D., Martinez D., Espinosa E. Efficacy of rechallenge with BRAF inhibition therapy in patients with advanced BRAFV600 mutant melanoma. Clin Transl Oncol. 2019;21(8):1061–1066. doi:10.1007/s12094-018-02028-0.; Simonaggio A., Michot J.M., Voisin A.L., Le Pavec J., Collins M., Lallart A. et al. Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer. JAMA Oncol. 2019. doi:10.1001/jamaoncol.2019.1022.; Reschke R., Ziemer M. Rechallenge with checkpoint inhibitors in metastatic melanoma. J Dtsch Dermatol Ges. 2020;18(5):429–436. doi:10.1111/ddg.14091.; Tedbirt B., De Pontville M., Branger P., Picard C., Baroudjian B., Lebbe C. et al. Rechallenge of immune checkpoint inhibitor after pembrolizumabinduced myasthenia gravis. Eur J Cancer. 2019;113:72–74. doi:10.1016/j.ejca.2019.03.006.; https://www.med-sovet.pro/jour/article/view/5707Test

الإتاحة: https://doi.org/10.21518/2079-701X-2020-9-80-93Test
https://doi.org/10.1200/JCO.2009.23.4799Test
https://doi.org/10.3322/caac.21409Test
https://doi.org/10.1016/j.jaad.2018.07.028Test
https://doi.org/10.1016/j.soc.2010.09.007Test
https://doi.org/10.1111/j.1468-3083.2009.03367.xTest
https://doi.org/10.1111/pcmr.12890Test
https://doi.org/10.1200/JCO.19.00489Test
https://doi.org/10.1111/bjd.15436Test
https://doi.org/10.1200/JCO.2010.32.4327Test